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Abstract 
Iodized oil, either injected or given orally, is the major alternative to iodized salt for 
controlling iodine deficiency. Oral administration has considerable advantages despite its 
shorter duration of effect. Little information is available on factors which influence the effect 
of orally administered iodized oil. In this dissertation the efficacy of oral iodized oil is 
studied with regard to the type of oil used, the dosage technique, intestinal parasites, 
nutritional status, sex and the consumption of raw cassava. The studies were carried out 
among Malawian school children. All results are based on iodine concentrations in casual 
urine samples collected at regular intervals after oral dosing with iodized oil. A model has 
been developed to describe the urinary iodine excretion pattern over time based on the 
retention and rate of elimination of iodine for subjects with different characteristics. The 
estimated durations of effectiveness were 13.7, 9.9 and 55.2 weeks for a single dose of 
iodized oil A (ethyl esters of iodized fatty acids; 490 mg iodine in 1 mL), a split-dose of oil 
A (2 x 245 mg iodine in 0.5 mL), and a single dose of iodized oil B (triacylglycerols; 675 
mg iodine in 1.25 mL), respectively. In general, the duration of effectiveness of iodized oil 
A was significantly increased in subjects treated for parasitic infestations. For Entamoeba 
histolytica it appears that the absorption of oral iodized oil A is greatly disturbed as the 
assessed duration of effectiveness was found to be only 2 weeks for the untreated subjects. 
Children with a relatively large subcutaneous fat mass retained more iodine than subjects with 
little subcutaneous fat. For goitrous subjects both the retention and elimination of iodine were 
increased. A reduction in midupper-arm circumference during the study increased the 
duration of effect. Based on the cumulative frequency distributions, of individually assessed 
durations of effectiveness, oral dosing with iodized oil was less effective in girls than in 
boys, and in those who consumed raw cassava than those who did not. 
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1 Introduction 
Endemie goiter and cretinism have been recognized as major world health 
problems for centuries. The primary etiologic factor, iodine deficiency, was identified in 
the 1890s although goiter was recognized in earliest history and treated by giving seaweed 
or burnt sponge to eat (1). Current estimates place 1,000 million people at risk of iodine 
deficiency of whom approximately one quarter are affected by goiter, the most noticeable 
feature of the disease (2). When severe, iodine deficiency can result in endemic cretinism. 
Less severe deficiency of iodine results in varying degrees of impairment of mental, 
psychomotor and physical development and increased risk of abortion and stillbirth in 
pregnant women. In order to cover this range of symptoms, Hetzel (3) introduced the 
term iodine deficiency disorders (IDD). Although the problem of IDD is worldwide, its 
major devastation is in developing countries even though available technology for its 
prevention makes it the micronutrient deficiency most amenable to quick and effective 
control and prevention (3-5). 
The following text provides a concise outline on iodine nutrition and methods of 
controlling IDD. Some background information is also given on iodine deficiency in 
Malawi and on the studies carried out in the framework of this research project on factors 
effecting retention, absorption and duration of effectiveness of oral iodized oil. 
Iodine nutrition 
IdÖine is an essential constituent of the thyroid hormones T4 (thyroxine or 
3,5,3'5'-tetraiodothyronine) and T3 (3,5,3'-triiodothyronine). The major role of iodine 
arises from the importance of thyroid hormones in growth and development of human 
beings and animals. 
The 1989 Recommended Daily Allowance (RDA) for iodine in the United States is 
in the range of 40-120 /ig for children up to the age of 10 years and 150 /ig for older 
persons. An additional 25 and 50 /ig are recommended during pregnancy and lactation, 
respectively (6). 
Iodine is mainly derived from food. In general, foods of animal origin, especially 
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marine fish, contain more iodine than those from plants. When produced on iodine-rich 
soils foods, both of animal and plant origin, contain more iodine than the same food from 
iodine-poor soils, thus a great variation is observed in the iodine content of foods. 
Furthermore, some of the iodine in food is lost with cooking and from what is left not all 
is absorbed (7). Iodine deficiency is likely to occur in populations living in areas where 
the soil has been depleted of its iodine content and where the people live only on locally 
grown food. 
Goitrogens 
Although lack of iodine is the most important factor in the development of goiter it 
has also been attributed to naturally occurring agents producing goitrogenetic and/or 
antithyroid effects. Antithyroid compounds can be divided into three categories according 
to the way in which they act on iodine metabolism (8). The first group comprises 
thiocyanates or thiocyanate-like compounds such as cyanogenic glycosides, and 
isothiocyanates. They are present in a variety of staple foods such as cassava, maize, 
bamboo shoots, sweet potatoes, and lima beans or they contain cyanogenic glycosides 
which release cyanide which is readily converted to thiocyanate in the body. Because of 
its chemical similarity to iodine, thiocyanate either ingested or released in the body 
inhibits the active process of iodine concentration in the thyroid gland, stimulates the 
active release of iodine from the thyroid, and may inhibit its binding in the gland. A 
second group of goitrogens comprises thiourea, thionamide-like goitrogens, thioglycoside, 
bioflavonoids, and aliphatic disulfides. These substance reduce thyroid hormone 
production in a complex manner by interfering with crucial steps in thyroid hormone 
synthesis within the thyroid gland. Isothiocyanates, mentioned in the first group of 
goitrogens, can react spontaneously with amino groups to form thiourea and thionamide-
like substances. Bioflavonoids are important constituents of a wide variety of plants. High 
concentrations have been found in various staple foods in tropical countries such as 
millet, sorghum, beans, and ground nuts. Aliphatic disulfides are present in onions and 
garlic. A third group of goitrogenetic substances, including excess iodine, calcium, 
fluoride and lithium, has been shown to interfere with thyroid function. Bacterial 
contamination, pollution, malnutrition and poor socioeconomic conditions appear to 
enhance the action of goitrogenetic factors in iodine-deficient areas (8). 
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Methods of controlling iodine deficiency 
There are three main approaches to increasing iodine intake: salt iodization; 
periodic administration of iodized oil; and fortifying water, food or condiments other than 
salt, with iodine. Salt iodization has proven to be an inexpensive, highly effective means 
of preventing iodine deficiency. Because of its cost effectiveness, salt iodization is the 
method of choice in most countries (9). However, it may not be a suitable means of 
iodine prophylaxis in areas where people consume salt only in small amounts or not at 
all, where salt production is a cottage industry, or where iodized salt production or 
importation is impractical or impossible for other reasons. In these situations, 
administration of iodized oil is an alternate means of iodine prophylaxis. In addition, this 
method is extremely useful as an interim measure during the preparatory phase prior to 
the introduction of general salt iodization. Both intramuscular and oral administration of 
iodized oil are safe, proven methods for the prevention and control of iodine deficiency. 
There is wide experience with using injections of iodized oil which provide effective 
prophylaxis for several years with some people claiming a duration of effectiveness up to 
5 years. However, programs using iodized oil injections require the expense of providing 
materials (needles, syringes and means to ensure that they are maintained sterile) and 
health workers qualified to give the injections. Such programs carry the risk of improper 
handling of needles with the consequent possibility of spreading viral diseases such as 
hepatitis B and the human immunodeficiency virus (HIV). Oral administration of iodized 
oil, on the other hand, has been used increasingly since 1974 despite the high variability 
in results and its shorter duration of effectiveness (10-15). Iodized oil, either in a capsule 
or from a dispenser, can be given by any responsible person without any medical or 
paramedical training. 
Iodine deficiency in Malawi 
In 1983 preliminary surveys were undertaken by Thilly and Swennen to assess the 
public health dimension of endemic goiter and the severity of iodine deficiency disorders 
in each of the three administrative regions in Malawi (16). It was estimated that 
approximately one million people were severely iodine deficient and that two million 
people lived in moderate endemic iodine-deficient areas. 
Since salt is not produced or processed in Malawi, non-iodized salt is imported 
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from South Africa. Thus, any decision to iodize salt in Malawi would require the building 
of new plants and warehouses. In contrast to the situation in many other countries, the 
distribution of iodized salt throughout the country would not be difficult. The main 
problem is that the total quantity of salt imported from neighbouring countries is 
insufficient to serve as the basis for a nationwide IDD control program. The best 
approach for Malawi would be to increase and to coordinate the importation of high 
quality salt and to take all the necessary steps to manufacture and distribute iodized salt. 
In 1985 those with goiter received an iodized oil injection and a registration card. 
The iodized oil injection campaign was planned to be repeated every four years. 
However, due to the high additional costs of the injection campaign, the Ministry of 
Health in Malawi decided in 1989 to switch to oral administration of iodized oil capsules 
(each providing 200 mg iodine per person) through the primary health care system. 
Presently iodized oil, either for oral used or for an injection, is available at the health 
centres in those districts where iodine deficiency is prevalent and upon request will be 
given to anyone who needs iodine supplementation. 
Until enough salt can be imported and iodized in Malawi, iodized oil will be 
needed in areas where moderate or severe iodine deficiency is prevalent. 
Study objectives 
The general aim of the studies described in this dissertation was to improve the 
effectiveness of oral administration of iodized oil in controlling iodine deficiency. The 
specific aims were firstly to compare the duration of effectiveness of a single oral dose of 
two preparations of iodized oil each containing the same dose of iodine. One preparation, 
initially developed for intramuscular injection, consists of ethyl esters of iodized fatty 
acids obtained from poppy-seed oil. It has been used in many national programs using 
oral iodized oil to combat iodine deficiency. The second preparation consists of 
triacylglycerol esters of iodized fatty acids from poppy-seed oil. It is more viscous than 
the ethyl ester preparation but quite suitable for oral use either in capsules or from a 
dispenser. The second specific aim was to study the effect of splitting the single dose of 
iodized oil, containing ethyl esters of iodized fatty acids, into two equal portions and 
giving them on two consecutive days. The fourth was to study the impact of intestinal 
parasites on the efficacy of orally administered iodized oil. The fifth specific aim was to 
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determine whether nutritional status, sex, energy balance and the consumption of raw 
cassava play a role in the iodine retention, the iodine elimination rate and the duration of 
effectiveness of orally administered iodized oil. 
In addition, we considered the appropriateness of using the ratio of iodine to 
creatinine in urine as an indicator for iodine status as all our results are based on the 
concentration of iodine in urine after dosing with iodized oil. 
Study design 
Subjects were selected from 8, 9, and 10-y-old children attending four primary 
schools in Ntcheu District, Malawi, where goiter is highly prevalent (16). The schools 
were selected on the basis of the number of pupils attending and on their accessibility 
from the main highway through Ntcheu District. The study was approved by the Ethics 
Committee of the National Council for Medical Research of Malawi in 1989. Informed 
consent for each child was obtained from a parent or guardian before the start of the 
study. As only apparently healthy subjects were considered suitable for enrolment in the 
study, all children were examined by a medical assistant from Ntcheu District Hospital. 
Children with a significantly enlarged liver or spleen, indicative of disease which may 
interfere with fat or protein metabolism, or with a mid upper arm circumference < 15.5 
cm, indicative of protein-energy malnutrition, were excluded from the study (n = 16). 
From the total group of apparently healthy subjects (n = 486) stool samples were 
examined microscopically for the presence of intestinal parasites. Those subjects with 
single intestinal parasites only (n = 120) were randomly allocated to receive or not to 
receive anti-parasitic therapy before oral administration of a single dose of iodized oil 
type A (ethyl esters of iodized fatty acids). All children with mixed infections (« = 334) 
received appropriate medication to treat their intestinal parasites. A group of 32 subjects 
had no intestinal parasites. The subjects who were either treated for their intestinal 
parasitic infestation or did not have intestinal parasites (n = 366) were randomly assigned 
to receive either a split dose of oil A (n = 39), a single dose of oil B (triacylglycerol 
esters of iodized fatty acids, n = 37), a carbohydrate rich drink 15-30 minutes prior to 
receiving a single dose of oil A (n = 38), neutral poppy-seed oil (n = 35) or a single 
dose of oil A (n = 217). 
Initial iodine status was calculated, per subject, as the average of two iodine 
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concentrations measured in two casual urine samples each of which were taken on two 
consecutive days, collected before iodized oil administration. Further, weight, height, 
four skinfolds (biceps, triceps, subscapular and supra-iliaca), midupper-arm circumference 
measures, goiter grades and demographic information were collected, at base-line, for 
each subject. 
For follow-up, urine samples were collected during the 4th, 8th, 20th, 40th, and 
44th week after iodized oil administration. In those weeks of measurement, three casual 
urine samples were collected; each one of three consecutive days. The average urinary 
iodine concentration per subject was calculated per week of measurement and was 
considered to reflect the iodine status during that particular week. The anthropometric 
data were collected at two/three monthly intervals. Goiters were graded 10 months after 
oral iodized oil administration. 
Outline of this dissertation 
The urinary iodine-creatinine ratio for evaluating iodine status is critically 
appraised in Chapter 2. In Chapter 3 a new model for describing urinary iodine excretion 
over time is introduced and subsequently used to compare retention, elimination and 
duration of effectiveness of different preparations of oral iodized oil. The impact of 
intestinal parasites on absorption, elimination and duration of effectiveness of oral iodized 
oil administration is studied in Chapter 4, while in Chapter 5 the effect of nutritional 
status, energy balance and goiter on oral iodized oil administration are considered. In 
Chapter 6 methods are proposed for assessing the prevalence rate of iodine deficiency, 
based on urinary iodine concentrations below 0.40 jimol/L, after oral dosing with iodized 
oil. These methods are used to compare the prevalence rates of iodine deficiency for the 
two types of iodized oil, for boys and girls and for the subjects who did and did not 
consume raw cassava. A general discussion is provided in Chapter 7. 
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2 A critical appraisal of goiter assessment and the ratio of urinary 
iodine to creatinine for evaluating iodine status* 
Carina A. Fumée, Frits van der Haar, Clive E. West and J. G. A. J. Hautvast 
Abstract 
Iodine status can be evaluated by goiter assessment and measurement of urinary 
iodine concentration in either 24-h urine collections or in casual samples. It is often 
impossible to make 24-h collections. Therefore, iodine concentration in casual samples is 
often expressed in terms of urinary creatinine, assuming creatinine excretion to be 
constant between and within individuals. In this study large inter and intraindividual 
variations were observed in the creatinine content of casual samples ranging from 0.6 -
9.87 mmol/L. Further, the urinary iodine-creatinine ratio correlated significantly with the 
creatinine concentration; Spearman's rank-order correlation coefficient, r, = 0.39 (P < 
0.001). If creatinine is a suitable parameter to correct for variations in iodine excretion, 
no correlation would be expected. We conclude that the iodine-creatinine ratio in casual 
urine samples is an unsuitable indicator for evaluating iodine status in areas where large 
inter and intra individual variations in urinary creatinine excretion exist. 
Introduction 
Assessment of goiter prevalence and measurement of urinary iodine in school-aged 
children are the methods most commonly used to determine whether and to what extent 
communities are affected by lack of iodine. Results from goiter assessment in a 
population often provide the stimulus for further research into the severity of the iodine 
deficiency problem. For urinary iodine excretion, measurement in 24-h samples is 
considered to provide a precise quantitative measure (1) but accurate collection of 24-h 
urine samples in the field is often not possible (2). Thus, in the assessment of the iodine 
status of populations, the concentration of iodine in casual urine samples is often related 
excretion of creatinine is constant not only between individuals but also within individuals 
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throughout the day and from day to day. 
In this study, the prevalence of goiter is assessed among 8, 9, and 10-y-old school 
children in Ntcheu, Malawi. Further, the appropriateness of relating iodine excretion in 
casual urine samples to that of creatinine for determining iodine status is evaluated. The 
data in this study were collected in Malawi as part of a research project on factors 
influencing the effectiveness of oral administration of iodized oil in combatting iodine 
deficiency. 
Subjects and methods 
Study design 
Subjects were selected from 8, 9, and 10-y-old school children (n = 502) 
attending four primary schools in Ntcheu District, Malawi, where goiter is prevalent (6). 
The schools were selected on the basis of having a sufficient number of pupils attending 
and on their accessibility as they were close to the main highway in Malawi which 
connects the Northern, Central and Southern Regions of the country. Informed consent 
for each child was obtained before the start of the study from parents or guardians. As 
only apparently healthy subjects were considered suitable for entry into the study, all 
children were examined by a medical assistant from Ntcheu District Hospital. Children 
with significantly enlarged liver or spleen, indicative of disease which may interfere with 
fat or protein metabolism, or with a midupper-arm circumference < 15.5 cm, indicative 
of protein-energy malnutrition, were excluded from the study (n = 16). Thyroid gland 
size was graded by two independent observers, using the palpation technique as 
recommended by the World Health Organization (WHO) (1). To maximize the accuracy 
of grading the thyroid size, the width of the thumb tip of the subject served as reference 
for normal thyroid size. As palpation provides rough measures only, the reproducibility 
was emphasized; in the case of an anomaly the lowest goiter grade was considered valid. 
Reproducibility within and between the observers was approximately 90 % and 80 %. 
From each subject, one casual urine sample per day was collected on each of two 
consecutive days (between 0730 and 1100) under the supervision of field assistants. 
Within 4 h of collection, approximately 1 g/L thymol was added to each sample. 
The study was approved by the Ethics Committee of the National Council for 
Medical Research of Malawi in 1989. 
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Urinary analysis 
Duplicate aliquots of urine were sent to the Department of Human and Animal 
Physiology of Wageningen Agricultural University where they were stored at -20°C prior 
to laboratory analysis. Iodine concentration in urine was assayed following alkaline 
digestion using the Sandell-Kolthoff reaction (7-9) adapted for use with a microtitre plate 
reader (Thermomax, Molecular Devices Corporation, Palo Alto CA, USA) coupled to a 
personal computer equipped with special software (Sofimax, Molecular Devices 
Corporation). The limit of detection or sensitivity, was 0.04 ^mol/L. Recoveries of iodate 
and iodide were 95 - 105 % and 92 - 100 %, respectively. All samples were assayed in 
duplicate and when measurements differed by > 10 % from their mean, the analysis was 
repeated in duplicate. The average of the duplicate measurements was used in the data 
analysis. Possible interference of the iodine assay by thiocyanate was examined by adding 
various amounts of potassium thiocyanate to a series of urine samples but the method was 
'found to be insensitive to the presence of thiocyanate. 
The creatinine concentration in the urine samples was determined by the Jaffé 
method (10) using the microtitre plate reader referred to above. The limit of detection 
was 0.1 mmol/L while precision was 0.2 mmol/L and 0.1 mmol/L for creatinine 
concentrations < 2 mmol/L and > 2 mmol/L respectively. Recovery was 100 %. All 
samples were assayed in triplicate and when measurements differed by > 5 % from the 
mean, the analysis was repeated in triplicate. The average of the three measurements was 
used in the data analysis. 
Statistical analysis 
The Statistical Package for Social Sciences (SPSS) was used for statistical analysis 
(11). Differences between days in urinary iodine excretion and creatinine were examined 
with Wilcoxon's signed-rank test. The non-parametric Mann-Whitney U test was used to 
examine associations between the prevalence of goiter and the concentration of iodine in 
urine in absolute terms and relative to urinary creatinine. The association between urinary 
iodine concentration, urinary creatinine concentration and the ratio of iodine to creatinine 
(iodine/creatinine) was examined using Spearman's rank-order correlation coefficient (rj. 
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Results 
Sixteen children with a mid upper arm circumference < 15.5 cm were excluded 
from the study and two children died of unknown causes before the study was completed. 
No children were found with enlargement of liver or spleen. The prevalence of total 
goiter in the study population was 56 % and 69 % for boys and girls respectively. From 
396 children, two casual urine samples were collected on two consecutive days and data 
have been presented for these children. 
Table 1 shows the variation in iodine concentration, creatinine concentration and 
iodine/creatinine in the casual urine samples collected from the school children (n = 
396). Large inter-individual variation was observed both in urinary iodine and creatinine 
excretion, ranging from 0-0.19 jtmol/L and 0.60 - 9.77 mmol/L respectively. The 
median intra-individual CVs for urinary iodine, urinary creatinine, and urinary 
iodine/creatinine were 39.2 %, 48.2 %, and 50.7 %, respectively. 
No statistically significant correlation was found between urinary iodine and 
urinary creatinine for the populations as a whole but for iodine concentrations < 0.40 
fimol/L, the correlation was statistically significant (rs = 0.49, P < 0.001). Furthermore, 
iodine concentration relative to that of creatinine in the whole population was 
significantly related to urinary creatinine concentration (r„ = 0.39, p < 0.001). Estimates 
of the severity of iodine deficiency based on the concentration of iodine 
in urine and on iodine-creatinine do not coincide (Table 2). No correlation was found 
between the size of the thyroid, as determined by either urinary iodine concentration or 
Table 1 Iodine concentration, creatinine concentration and the ratio of iodine to creatinine 
in casual urine samples from schoolchildren in Ntcheu District, Malawi1 
Iodine Creatinine Iodine/creatinine 
/xmol/L* mmol/L* 
Day 1 0.20 (0.05 - 1.86) 3.70 (0.92 - 9.77) 52.1 (17.6 - 315.4) 
Day 2 0.09 (0.02 - 0.44)2 2.50 (0.60 - 7.00)3 37.5 (11.1 - 162.5)4 
Average of both days 0.15(0.06-0.75) 3.15(1.35-7.19) 44.8(17.8-211.2) 
1
 Values are medians; 5th and 95th percentile in parenthesis, n = 396. 
2,3,4
 Significantly different from day 1 value (Wilcoxon's signed-rank test for 
matched pairs) 2P < 0.001 (Z = -10.7), 3P < 0.001 (Z = -6.79), *P < 0.001 
(Z = -8.13). 
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Table 2 Classification of the severity of iodine deficiency among school children by 
urinary iodine concentration and the ratio of iodine to creatinine in Ntcheu District, 
Malawi1 
Categories of iodine 
deficiency 
None 
Mild 
Moderate 
Severe 
Iodine/creatinine2 
> 89.1 (16.9) 
44.6-89.1 (49.9) 
22,3-44.6 (36.1) 
< 22.3 (7.0) 
Iodine concentration3 
> 0.79 (4.3) 
0.40 - 0.79 (6.0) 
0.16-0.40 (38.4) 
< 0.16 (51.3) 
1
 n = 396. Percent of subjects in parentheses. 
2
 Based on the WHO indicators (1). 
3
 Based on the WHO/UNICEF/ICCIDD (International Council for Control of 
Iodine Deficiency) indicators (unpublished observations, 1993). 
Table 3 Prevalence of goiter by stage, and average urinary iodine concentration among 
school children by sex and age, in Ntcheu District, Malawi 
Number of goitrous 
subjects 
8y 
9 y 
10 y 
Total 
Average iodine 
concentration (/imol/L)1 
8y 
9 y 
10 y 
Total 
0 
5 
40 
42 
87 
0.14 
0.23 
0.15 
0.16 
Boys 
1A 
8 
35 
40 
83 
0.15 
0.14 
0.20 
0.17 
IB 
0 
12 
15 
27 
-
0.12 
0.20 
0.14 
0 
4 
26 
32 
62 
0.21 
0.15 
0.17 
0.16 
Girls 
1A 
15 
46 
44 
105 
0.11 
0.16 
0.17 
0.16 
IB 
1 
9 
22 
32 
0.41 
0.11 
0.20 
0.16 
2 
0 
0 
1 
1 
-
0.10 
0.19 
0.17 
1
 Based on mean iodine concentration of day 1 and 2 per subject. 
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iodine concentration expressed in terms of creatinine using the non-parametric Mann-
Whitney U test. The number of goitrous subjects was higher among girls than in boys as 
can be seen in Table 3. However, there was no difference between the sexes in urinary 
iodine concentration expressed in absolute terms. 
Discussion 
In this study we assessed a prevalence of total goiter among 8, 9, and 10-y-old 
children and found percentages of approximately 56 and 69 % for boys and girls, 
respectively. The median iodine concentration, average of two consecutive days, confirms 
the presumption, based on the goiter assessment, of a significant health problem in 
Ntcheu District as a result of iodine deficiency. We believe that a goiter survey is a good 
measure for assessing iodine deficiency in a population. School children can be regarded 
as a healthy sub-sample of a population and they are conveniently accessible. A goiter 
prevalence of 5 %, or more among school aged children indicates that iodine deficiency is 
a public health problem which requires attention. The cut-off of 5 % allows some margin 
for the inaccuracy of goiter assessment and causes for goiter other than iodine deficiency 
(13). 
No apparent differences were found for absolute urinary iodine concentration 
between the sexes in the three age groups. However, the prevalence of goiter was highest 
among the girls which indicate that girls are at a higher risk for developing goiter than 
boys. 
Daily urinary excretion of iodine closely reflects iodine intake, and has been used 
as a measure of iodine status in many large-scale nutrition surveys (11). Because it is 
often impossible to collect 24-h samples of urine, urinary iodine concentration is often 
expressed in terms of urinary creatinine in order to correct for variations in urinary 
output. However, iodine/creatinine correlated highly with urinary creatinine. If relating 
iodine concentration to that of creatinine excretion is appropriate, its correlation 
coefficient should approach zero. Thus our results demonstrate that expressing urinary 
iodine concentration in terms of urinary creatinine concentration is not appropriate. These 
findings are consistent with those of Greenblatt et al (5) and Bourdoux et al (2,12). 
Despite variations in urine output, urinary iodine concentration remains a valuable 
and useful parameter for assessing current iodine status in a population, especially when 
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possibilities for the assessment of blood parameters are absent. As it is often not possible 
to follow large groups of subjects for a long time when measurements are complicated, 
time consuming or expensive we suggest that fewer subjects can be used provided that 
corrections are made for the day-to-day variation in urinary output. This can be achieved 
by repeated sampling per subject thus retaining a high level of precision and power. 
Therefore we suggest that iodine concentration should be measured in two or more casual 
urine samples from the same individuals taken on consecutive days. Two urine samples 
from a approximately 40 randomly selected school children would provide a adequate 
quantitative measure of the current status of iodine intake with a power of 0.8 and 95 % 
confidence. When three urine samples are taken, the population size required to reach the 
same power and confidence can be reduced to 21 subjects. WHO/UNICEF/ICCIDD has 
recently suggested modified cut-off points to assess the severity of iodine deficiency by 
measuring the iodine concentration in casual urine samples (13). Using their criteria, 95.7 
% of the children in this study would be regarded as deficient (urinary iodine 
concentration < 0.79 jtmol/L) of whom 51.3 % were classified as severely deficient 
(urinary iodine concentration < 0.16 /tmol/L). 
As the mean and median urinary iodine concentrations do not coincide, indicating 
that the distribution is not symmetric, it is appropriate to evaluate iodine deficiency at the 
population level in terms of the median or the log of the mean iodine concentration in 
urine. It is not appropriate to use the mean without it being log transformed as the 
extreme values dominate its value. The median urinary iodine excretion level was 0.16 
/iinol/L which, in terms of the criteria laid down by WHO/UNICEF/ICCIDD (13) 
indicates that Ntcheu District is severely iodine deficient. 
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New model for describing urinary iodine excretion: its use for comparing different 
oral preparations of iodized oil* 
Carina A. Fumée, Gerard A. Pfann, Clive E. West, Frits van der Haar, 
Daan van der Heide and Joseph G.A.J. Hautvast 
Abstract 
Urinary iodine concentration, after oral dosing with iodized oil, reflects the mutual 
effects of the physiological mechanisms involved in the retention and elimination of 
iodine. A model has been used to describe the urinary iodine excretion over time. As 
efficacy is determined by retention and elimination a model-based duration of 
effectiveness can be assessed. They were estimated to be 13.7, 9.9 and 55.2 weeks for a 
single dose of iodized oil A (ethyl esters of iodized fatty acids; 490 mg iodine), a split-
dose of oil A (2 x 245 mg iodine), and a single dose of iodized oil B (triacylglycerol 
esters of fatty acids; 675 mg iodine), respectively. Compared to oil A, the iodine 
retention and elimination of oil B were significantly increased. Dividing the dose of oil A 
into two equal amounts given on consecutive days did not improve efficacy. 
Introduction 
Iodine deficiency has been a major world health problem for centuries (1). 
Although salt iodisation is the usual control method of choice, dosing with iodized oil is 
often used before salt iodisation can get under way. Because of the extra costs and health 
risks associated with dosing parenterally, oral dosing with iodized oil is increasingly being 
used in iodine deficiency control programs (2). There are a number of iodized oil 
preparations based on poppy-seed oil for both injections and oral use. One type of oil (oil 
A), initially developed for intra-muscular administration, is a mixture of ethyl esters of 
iodized fatty acids (separated fatty acids which have been iodized) while in an other type 
of oil (oil B), the iodized fatty acids are present as triacylglycerol esters (three iodized 
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fatty acids esterified with glycerol). The latter, which is cheaper to produce, is more 
viscous but quite suitable for oral use both as capsules and from a dispenser. Since the 
chemical nature of iodized oil preparations can influence their effectiveness in combatting 
iodine deficiency (3), we compared iodine excretion in urine after oral dosing with either 
oil A or oil B. It is expected that oil B is absorbed from the small intestine as neutral fat 
which consists of triacylglycerol esters. The mechanism by which ethyl esters are 
absorbed remains unclear. In addition, the effect of giving half of the total dose of oil A 
on each of two consecutive days (split dose) on oral iodine excretion was also examined. 
In order to compare the different treatments, we have first examined the empirical 
performance of two statistical models to describe the urinary iodine excretion pattern 
through time after oral dosing with iodized oil. The first model is a single exponential 
equation which can be easily translated into a 1 compartment model, in which the iodine 
elimination rate remains constant over time. If the rate of iodine elimination after oral 
dosing with iodized oil changes over time, it may be expected that more than one 
mechanism is involved in the process of iodine decay. In this case, the iodine 
concentration in the urine always reflects the grand total of the mutual effects of the 
mechanisms involved in iodine elimination. Such an elimination process can be described 
using a hyperbolic function of urinary iodine excretion over time. An encompassing 
equation nesting both the single exponential and the hyperbolic model was used to test 
which of the two models most accurately described the urinary iodine excretion pattern 
after oral iodized oil administration. That model is used for the subsequent analysis to 
compare the different treatment groups used in this study. 
Subjects and methods 
Subjects 
Apparently healthy 8, 9, and 10-y-old school children, treated for mixed intestinal 
parasitic infestations, from four schools in Ntcheu District, Malawi, were selected to 
participate in the study (n = 326). The study was approved by the Ethics Committee of 
the National Council for Medical Research of Malawi in 1989. Informed consent for each 
child was obtained from the parents or guardians before the study commenced. The 
children were examined by a medical assistant from Ntcheu District Hospital. 
From the total group of subjects three small groups of 37, 39 and 35 subjects were 
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randomly selected, by age and sex, to received either a single dose of 1.25 mL oil B 
(Oriodol, 540 mg iodine in 1 mL, Laboratoire Guerbet, Aulnay-sous-Bois CEDEX, 
France), 0.5 mL oil A (Lipiodol UF, 490 mg iodine in 1 mL, Laboratoire Guerbet) on 
each of two consecutive days (2 x 245 mg iodine), or 1 mL of neutral poppy seed oil (no 
iodine, Laboratoire Guerbet). All other subjects (n = 217) served as controls and 
received a single dose of 1 mL oil A (490 mg iodine). The placebo group (neutral poppy 
seed oil) was use to signal possible interference of uncontrolled sources of iodine and 
received iodized oil after 44 weeks. The doses of iodized oil were administered orally 
using dispensers (Englass Dispensing Devices, The English Glass Co. Ltd., Leicester, 
England) delivering 0.5 mL (oil A, split dose), 1.0 mL (oil A, single dose or neutral 
poppy seed oil) or 1.25 mL (oil B). 
Thyroid size was graded by two independent observers using the palpation 
technique as recommended by the World Health Organization (4,5). For all subjects the 
goiter grading was done by the same persons, before and 10 months after oral iodized oil 
administration. In case of doubt the lowest goiter grade was recorded. Reproducibility 
within and between the observers was approximately 90 % and 80 %. 
Measurement of urinary iodine excretion was based on the concentration of iodine 
in casual urine samples. The samples were collected during the morning under the 
supervision of two field assistants. At baseline, iodine status, per subject, was determined 
from the average iodine concentration in two casual urine samples each collected on two 
consecutive days before iodized oil administration. Subsequent values were based on the 
average of the iodine concentration in three urine samples each collected on consecutive 
days during the 4th, 8th, 20th, 40th and 44th week after oral iodized oil administration 
(5). 
Urinary analysis 
All urine samples, preserved with thymol, were sent to the Department of Human 
and Animal Physiology of Wageningen Agricultural University where they were stored 
at -20°C prior to laboratory analysis. Iodine was assayed following alkaline digestion 
using the Sandell-Kolthoff reaction (6-8) adapted for use with a micro titre plate reader 
(Thermomax, Molecular Devices Corporation, Palo Alto CA, USA) coupled to a personal 
computer equipped with special software (Sofimax, Molecular Devices Corporation). All 
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samples were assayed in duplicate and when measurements differed by < 10% from their 
mean, the analysis was repeated in duplicate. 
Modelling iodine excretion over time 
If iodine, after oral dosing with iodized oil, is excreted from the body in the urine 
at a constant rate its relationship with time can be described in an exponential one-
compartment model (9): 
IT = c^exp^T), a t > 0, 7, > 0; (Model 1) 
where IT = urinary iodine concentration at time T; 
T = time (w) after dosing; 
at = urinary iodine concentration at T = 0; 
7, = constant parameter relating urinary iodine 
excretion to the amount of iodine in the body. 
An exponential two-compartment model, which can be used when two distinct 
linear phases determine iodine decay, yields the following expression: 
IT = ax exp(-7xT) + ay exp(-7yT) 
In general, however, the number of phases of iodine elimination is unknown a 
priori, while the aggregate effects of multiple mechanisms are observed as the 
concentration of iodine in the urine through time. We propose a multi-phase iodine 
elimination model to describe the relationship between iodine excretion and time without 
fixing the number of excretion mechanisms involved in advance. This multi-phase model 
of the process of iodine decay is as follows: 
IT = a2 T"2, a2 > 0, JÎ2 > 0; (Model 2) 
where IT = urinary iodine concentration at time t; 
T = time (w) after dosing; 
a2 = retention capacity; 
R2 = iodine elimination rate. 
Given estimates for a2 and ß2 and the value of I* (urinary iodine concentration values 
associated with iodine deficiency (unpublished observations; UNICEF/WHO/ICCIDD 
1993), the model-based duration of effect, T', can be calculated. In this study I* was 
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chosen to be 0.40 /*mol/L which is associated with moderate iodine deficiency. 
Finally, in order to test which of Models 1 and 2 most accurately describes the 
pattern of iodine excretion in urine over time, the following encompassing equation can 
be used which nests both models: 
IT = «i,2 T""2 e x p ^ T ) , a12 > 0, ^ > 0; y ^ 0; (Model 3) 
If 7! = 0, Model 3 equals Model 2; whereas if/32 = 0, Model 3 equals Model 1. 
Statistical analysis 
The urinary iodine concentrations of those subjects with at least one observation at 
each of the five points of measurements were considered for statistical analysis (n = 
208). For each subject with more than one observation per week of measurement, the 
average iodine concentration was calculated. 
At base-line the control group, the two treatment groups and the placebo group 
were compared using descriptive statistics with regard to nutritional indicators (mean, 
SD), total goiter and iodine status (median urinary iodine concentration and 25fh and 75th 
percentile). 
The median urinary iodine concentration per measurement point in the two 
treatment groups (split-dose oil A and oil B) was compared to that in the control group 
(oil A) using the k-sample median test (10). In short, a 95 % CI was estimated around the 
median, per treatment group, using its + 2 SD. If the median value of the control group 
did not fall within the interval of the treatment group the difference is reported 
statistically significant (P < 0.05). 
The models, transformed into log-linear equivalents, were fitting to the five 
measuring points of urinary iodine concentration in the control group and the two 
treatment groups. The parameter au a2, R2, and yt were estimated using the maximum 
likelihood estimation technique (11) in which each individual average urinary iodine 
concentration is considered. Measurement errors were assumed to be log-normally 
distributed (see footnote of Table 2). Student's t-statistics were used to test for differences 
between the estimated coefficients ß2 and ?! of Model 3 for the oil B and oil A split-dose 
group versus the controls (oil A single dose) to infer which of the two non-nested models 
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describes the data better. Multiple regression methods were used to test for difference in 
the efficacy of iodized oil in the control group and the two treatment groups. 
Results 
A description of the 8, 9, and 10-y-old boys and girls in the control group, the 
two treatment groups and the placebo group, with regard to weight, height, mid upper 
arm circumference and total goiter, is given in Table 1. The 4 groups were comparable. 
In Table 2, the descriptive statistics on urinary iodine at base-line (w = 0) and 
after dosing (w = 4, 8, 20, 40, and 44) are presented. There was no difference in urinary 
iodine concentration between the 4 groups at baseline. For those who had received 1.25 
mL oil B (675 mg iodine), the urinary iodine concentration 4 w after dosing was 
significantly higher than in the other groups receiving iodized oil and this difference 
persisted throughout the period of observation up to 44 w (P < 0.001). For both groups 
in which the subjects had received 1 mL oil A either as a single dose (490 mg iodine) or 
Table 2 Descriptive statistics on urinary iodine concentrations (jimdUL) for the control 
group, the two treatment groups and the placebo group1"3 
Time Oil A Oil B Oil A Poppy-seed oil 
w 1 x 1.0 mL 1 x 1.25 mL 2 x 0.5 mL 1 x 1.0 mL 
n = 122 n = 33 n = 24 n = 29 
0 
4 
8 
20 
40 
44 
0.15 
(0.11,0.23) 
1.07 
(0.43, 2.60) 
0.37 
(0.17, 0.88) 
0.27 
(0.13, 0.54) 
0.32 
(0.16, 0.54) 
0.23 
(0.09, 0.40) 
0.17 
(0.12, 0.26) 
4. II2 
(2.53, 7.00) 
1.502 
(0.94, 3.62) 
1.042 
(0.41, 1.65) 
0.802 
(0.48, 1.21) 
0.412 
(0.23, 0.79) 
0.16 
(0.12, 0.26) 
0.542 
(0.25, 2.23) 
0.24 
(0.17, 0.55) 
0.27 
(0.15, 0.50) 
0.30 
(0.14, 0.57) 
0.14 
(0.05, 0.35) 
0.19 
(0.10,0.40) 
0.122 
(0.08, 0.29) 
0.082 
(0.05, 0.15) 
0.052 
(0.04, 0.12) 
0.16 
(0.07, 0.30) 
0.09 
(0.03, 0.23) 
1
 25 percentile and 75 percentile are given in parentheses. 
2
 P < 0.05 comparing other columns to the first at each measuring point. 
3
 Oil A is Lipiodol UF, oil B is Oriodol. 
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a split dose (2 x 245 mg iodine) a large decrease in urinary iodine concentration was 
observed from week 4 to 8. 
The urinary iodine concentration in the control and placebo group increase slightly 
during week 40 (not significant) as compared to week 20. In the placebo group urinary 
iodine remained low throughout the study indicating that there was no iodine 
contamination. 
In Table 3, the parameters values obtained from the three models are presented. 
For both Model 1 and Model 2, the estimates of J^ an(^ 71 a r e significant. For all three 
treatment groups the standard errors of the regression coefficient for Model 2 are smaller 
than for Model 1 (82 < ôj). This implies that Model 2 fits the data better than Model 1. 
For Model 3 (encompassing model), the estimates of &% are positive and significant 
whereas the estimates of 7^ are all negative violating the requirements of the model, and 
insignificant for oil B and the split-dose of oil A, further supporting the conclusion that 
Model 2 is superior to Model 1. Thus, for comparison of iodine retention and elimination 
and the duration of effectiveness between the three treatment groups only the urinary 
iodine excretion pattern as described by Model 2 is used for subsequent statistical 
analysis. 
A graphical representation of the data using Model 2 is presented in Figure 1. 
Iodine concentration in urine remained above the level regarded as moderately iodine 
deficient, I* < 0.40 /tmol/L (9), much longer in the oil B group (T* = 55 w) than in the 
oil A groups (see also Table 4). Dividing the dose of oil A over two days did not improve 
the efficacy of oral iodized oil administration. 
In Table 4, the values for iodine retention (c^) and elimination (fij) assessed using 
Model 2 are presented. Both parameters are significantly higher in the oil B group than in 
the oil A group. No differences in retention and elimination were found between the 
single and split-dose oil A groups. 
Before oral iodized oil administration the total goiter prevalence was 55.2% and 
68.3% for all boys and girls, respectively. Ten months later, total goiter among the 
subjects who had received iodized oil was reduced by < 80 % to 12.4 and 16.7 % for 
boys and girls, respectively. There were no differences in total goiter between the control 
group and the 2 treatment groups. In the placebo group total goiter increased with 7.4 %. 
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Table 3 Comparison of urinary iodine patterns after treatment with oil A (single dose or 
split-dose) or oil B (single dose) based on three models1"3 
a ß 7 ô4 
IX oil A 
Modell 0.613(16.11) -- 0.023(10.55) 1.091 
Model 2 1.372 (8.99) 0.480(12.73) -- 1.066 
Model 3 3.873 (4.57) 1.207 (8.76) -0.043 (-5.48) 1.051 
Model 1 3.082 (7.30) - 0.046 (9.31) 0.990 
Model 2 11.765 (4.20) 0.860(10.53) -- 0.944 
Model 3 20.374(2.13) 1.249(4.19) -0.023 (-1.36) 0.942 
Model 1 1.258 (3.35) - 0.027 (4.60) 1.055 
Model 2 0.566 (6.08) 0.512 (4.99) -- 1.041 
Model 3 1.638(1.68) 0.697(1.85) -0.011 (-0.51) 1.044 
1
 Model 1: In IT = In <*i - y{T + e„ e, ~ N (0,(oj)2); 
Model 2: In IT = In a2 - ^ In T + e2) e2 ~ N (0, (S^2); 
Model 3: In IT = In a, 2 - ß2 In T - y{ï + e3, e3 ~ N (0,(oj)2); where e1>2t3 are log-
normally distributed residuals and ôUi3 are the standard deviations of the regressions. 
2
 Students t-values are given in parentheses. 
3
 Oil A is Lipiodol UF; oil B is Oriodol. 
4
 5 denotes the standard error of the regression. 
1 X oil B 
2 X oil A 
Table 4 Iodine retention, elimination and the model-based duration of effectiveness after oral 
administration of iodized oil for school children given either a single dose of oil A, a single 
dose of oil B or a split dose of oil A12 
1 X 1 mL oil A 1 X 1 mL oil B 2 X 0.5 mL oil A 
(n = 122) {n = 33) (n = 24) 
Retention (a2) 1.372 (9.00) 11.765 (4.20) 1.258 (3.35) 
Elimination (ß2) 0.480(12.73) 0.860(10.53) 0.512 (4.99) 
Duration of effectiveness (T') 13.731(13.66) 52.510(6.99) 9.854(4.84) 
Test:
 aüaUaM = acailrol 10.939 (9.02) -0.114 (-0.29) 
Test: B Ä = Rcootrol 0.380 (4.65) 0.032 (0.31) 
Test: T * ^ ^ , = T*conlrol 38.779 (5.61) -3.876 (-1.90) 
1
 Asymptotic Student's t-values are given in parentheses. 
2
 Oil A is Lipiodol UF; oil B is Oriodol. 
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Figure 1 Urinary iodine excretion (in natural logarithms) after oral iodized oil 
administration as described by Model 21,2 
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 For description of Model 2, see text. I* is the level of urinary iodine 
concentration indicating moderate iodine deficiency (0.40 /*mol/L). 
2
 Oil A is Lipiodol UF; oil B is Oriodol. 
Discussion and conclusions 
The basic principles for approaching the data in this study with exponential 
compartment models have been derived from pharmacokinetics and toxicokinetics (12). 
The underlying theoretical assumption for using the theoretical exponential one-
compartment model (Model 1) is that the proportion of iodine in the body which is 
excreted in the urine is constant over time. Alternatively, we considered a model (Model 
2) in which the iodine excretion rate varies through time, without making a prior 
assumption about the number of processes involved in the elimination of iodine. This 
model can be described as a hyperbolic relation between the rate of iodine excretion and 
time passed after oral administration of iodized oil. It enables us to determine the 
retention capacity and the duration of effectiveness, even though the excretion rate may 
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change through time. Given the number of observations in this study, Model 2 does not 
allow the unravelling of the number physiological processes involved in iodine 
elimination. Studies for such purposes would best be done under laboratory conditions 
possibly using radioisotopes. However, an additional advantage of Model 2 is that we can 
draw conclusions from its parameters by introducing variables for subject-specific 
characteristics including binary variables, such as sex and presence/absence of infection 
and continuous variables, such as age and anthropometric parameters. For this purpose 
the model can be extended as follows: 
KT,x) = ( a 0 + a1x)T-(»°+B^>, 
where I = urinary iodine concentration; 
T = time (w) after dosing; 
x = subject specific characteristics 
a 0 1 = r e t en tion capacity; 
BQ J = iodine elimination rate. 
The values in Table 2 show a rapid decrease from week 40 to 44 in oil B and a 
slight increase in oil A from week 20 to 40. Model 2, as used in this study, does not 
account for the ups and downs in iodine excretion which may be induced by seasonal 
characteristics. As shown above, the model is suitable for inclusion of explanatory 
variables which will facilitate further research into factors which influence the efficacy of 
oral iodized oil. 
So far no information is available on the effectiveness of orally administered 
iodized oil for control of iodine deficiency. Four studies describe little or no difference 
between injected and orally administered iodized oil during a period of 2 years follow up 
(13-15). However, when Bautista et al dosed children orally with iodized oil type A 
(containing 400 mg iodine), they found that urinary iodine levels returned to base-line 
levels after 6 months (16). Eltom et al demonstrated a single oral dose of 2 capsules 
containing iodized type A oil (400 mg iodine, ethyl esters of iodized fatty acids) to be 
effective for at least two years in school children (17) while Tonglet et al (18) reported 
that urinary iodine concentrations in adults remained normal for 6-9 months after oral 
dosing with 0.1 (47 mg iodine) and 0.25 mL (118 mg iodine) of the same type of iodized 
oil. In this study, 1 mL oil A (490 mg iodine) was found to be effective for 13.7 w which 
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is in line with the findings of Bautista et al (16). However, oral dosing with the same 
dose of 675 mg iodine in 1.25 mL oil B was found to be effective for approximately 55 
weeks. Although the subjects in the oil B group had received 27 % more iodine than in 
the oil A group a four-fold increase in duration of effectiveness is striking. It was 
intended to provide equal doses of iodine in all groups. Although this was not achieved, it 
is clear that oil B is more effective than oil A. Thus the triacylglycerol ester preparation 
is to be preferred to the ethyl ester preparation. Fortunately it is also cheaper. 
In studies in China, both iodized soybean and walnut oil (triacylglycerol esters) 
have been used orally (14,15). Although no data are available for urinary iodide excretion 
in the first six months, data from six months to three or four years after oral dosing 
suggest that the iodized soybean oil provides protection for a longer period of time than 
iodized walnut oil. Assuming that the preparations are comparable in properties such as 
iodine content (bound and free), the difference could perhaps be attributed to the number 
of iodine atoms in each triacylglycerol molecule or fatty acid moiety. Since soybean oil 
contains less polyunsaturated fatty acids (ca 60 % linoleic and linolenic acid) than walnut 
oil (ca 75 % linoleic and linolenic acid), it would contain less iodine per triacylglycerol 
molecule than walnut oil. This may lead to a greater retention of iodine from the iodized 
soy bean oil compared with the walnut oil which is in line with the results of the work of 
Van der Heide et al (3) in both humans and rats. They found that iodized olive oil (ca 10 
% linoleic acid) was more effective than iodized ethyl esters of fatty acids from poppy 
seed oil (oil A, ca 60 % linoleic acid). However, in these experiments they compared 
preparations differing not only in fatty acid composition but also differing in contains of 
ethyl esters and glyceryl esters. In the present study using poppy seed oil-based 
preparations, the triacylglycerol preparation (oil B) was more effective than the mixture 
of ethyl esters of iodized fatty acids (oil A). 
Administration of the iodized oil (oil A) in two equal doses on two consecutive 
days did not improve the efficacy of the treatment. Thus there is no advantage of splitting 
the dose although repeating the dosing after a break of more than 2 days may prove to be 
effective. It is somewhat surprising to note that Tonglet et al (18) found that single doses 
of small amounts of oil A (47 mg and 118 mg) were effective in maintaining adequate 
urinary iodine levels for 6 to 9 months. Based on our work with children, such low doses 
cannot be recommended at least in children. In fact, most studies carried out so far (13-
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15, 16-19) have reported adequate levels of iodine excretion in urine over a longer period 
of time than we found in children. In this paper, the shortest period of protection against 
iodine deficiency ever reported is presented. It may be that the dosage required by 
children is higher because of lower retention, more rapid excretion or even higher 
requirements. 
The reduction of total goiter rates, in this study, after oral administration of 
iodized oil to about one quarter of those previously is in line with results reported by 
Watanabe et al (13) but more pronounced than that described by other authors (14-17). 
No differences in total goiter reduction was found between the treatment groups but this 
may be due to the relatively small number of subjects in the different groups. 
Furthermore, this study did not last long enough to permit the study of goiter recurrence 
which may be related to the amount of iodine stored in the thyroid after oral dosing. 
The wide variation in efficacy of oral iodized oil remains. Possible explanations 
for some of the differences observed may be explained by the severity of the initial iodine 
deficiency, goiter and by the age and sex of the subjects (20). In addition, the presence of 
intestinal parasites, the nutritional status and the energy balance at the time of giving the 
oral dose may interfere with absorption and metabolism of the iodized oil and the storage 
and subsequent release of iodine in the body. Further research needs to be carried out to 
study the impact of these factors. 
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4 The impact of intestinal parasites on the efficacy of oral iodized oil 
in controlling iodine deficiency 
Carina A. Fumée, Clive E. West, Frits van der Haar, and Joseph G.A.J Hautvast 
Abstract 
Subjects with a single parasitic infestation, Entamoeba histolytica, Ascaris 
lumbricoides, or hookworm were randomly allocated, per parasite type, to receive 
(treated) or not receive (untreated) anti-parasitic therapy prior to an oral dose of iodized 
oil (ethyl esters of iodized fatty acids). Urinary iodine concentrations were measured at 
regular intervals after the intervention to evaluate the duration of effectiveness. For the 
untreated subjects in general the duration of effectiveness was 9.2 weeks shorter (P < 
0.001) than for their treated counterparts (16.8 weeks). Treatment of subjects infested 
with Entamoeba histolytica increased the duration of effectiveness from 2 to 21 weeks. 
Introduction 
Iodine deficiency exists in areas where the soil has been depleted of iodine and the 
diet of the population predominantly consists of locally grown foods (1). Salt iodization is 
an inexpensive, highly effective means for preventing iodine deficiency (2). However, 
difficulties and delays in achieving effective salt iodization in areas where iodine 
deficiency requires immediate attention, demand other measures. The major alternative to 
salt iodization is iodized oil given either by injections or orally (3). There is wide 
experience with injecting iodized oil which provides effective prophylaxis for periods 
possibly up to five years (4). Administration of iodized oil orally has practical advantages 
over injections and has been used increasingly since 1974. However, the results are 
highly variable and its duration of effectiveness is shorter ranging from 6 months to two 
years (5-10). Factors which may influence the absorption and retention of oral iodized oil 
have so far received little attention. This study compares the efficacy of oral dosing with 
iodized oil in subjects who have or have not received anti-parasitic medication to treat 
either Entamoeba histolytica, Ascaris lumbricoides or hookworm prior to receiving 
iodized oil orally. 
Subjects and methods 
Subjects 
Subjects were selected from 8, 9, and 10-y-old school children (n = 502) 
attending four primary schools in Ntcheu District, Malawi, where goiter is highly 
prevalent. The schools were selected on the basis of having a sufficient number of pupils 
attending and on their accessibility as they were close to the main highway in Malawi 
which connects the Northern, Central and Southern Regions of the country. The study 
was approved by the Ethics Committee of the National Council for Medical Research of 
Malawi in 1989. Informed consent was obtained from parents or guardians of each child 
before the onset of the study. As only apparently healthy subjects were considered 
suitable for entry into the study, all children were examined by a medical assistant from 
Ntcheu District Hospital. Children with significantly enlarged liver or spleen, indicative 
of disease which may interfere with fat or protein metabolism, or with a midupper-arm 
circumference below 15.5 cm, indicative of protein-energy malnutrition, were excluded 
from the study (n = 16). 
Intestinal parasites 
From the total group of apparently healthy subjects two fecal specimens each taken 
on two consecutive days were collected and microscopically examined immediately, in 
duplicate by the Kato thick smear technique using approximately 50 mg of stool to detect 
parasite ova (11,12). Eosine dye (2% eosin in saline) and potassium iodo-iodide colouring 
(3 g potassium iodide and 2 g iodine in 100 mL water) was used for detection and 
determination of flagellates and amoebae (12). Egg counts were recorded for Ascaris 
lumbricoides and hookworm and a qualitative record was kept for all other parasites and 
different species of amoeba and specifically for Entamoeba histolytica (10 X objective; 
cysts 10-15 /xm in diameter, round, 2-4 nuclei). A subject was classified as a cyst passer 
if Entamoeba histolytica cysts were detected on two direct smear slides. All stool samples 
were examined by an experienced microscopist of the Bilharzia Research Institute, 
Lilongwe, Malawi. One in every ten stool samples was evaluated by a parasitologist of 
the Department of Intestinal Parasitology of Kamuzu Central Hospital, Lilongwe, Malawi, 
46 
to ensure correct diagnosis. The laboratory tests were carried out in a field laboratory 
with limited equipment. 
Study design 
This study is one of a number of studies on factors which may affect retention, 
elimination and effectiveness of oral iodized oil administration for control and prevention 
of iodine deficiency. The effect of treating intestinal parasites on the effectiveness of oral 
iodized oil in general was studied in a randomized double blind intervention study. In 
addition, the effect of treating Ascaris lumbricoides, hookworm and Entamoeba histolytica 
infestations was studied specifically because of their prevalence within the study 
population. 
Following examination of the stool samples in the total group of children (n = 
502), those classified as Entamoeba histolytica cyst passers (n = 34) or infested with 
Ascaris lumbricoides (n = 33) or hookworm (n = 53) only, were randomly allocated, per 
parasite group, either to receive (treated) or not to receive (untreated) either the broad 
spectrum anti-helminth albendazole (Alzental, Shin Poong Pharm. Co. Ltd., Seoul, South 
Korea) or the broad spectrum antimicrobial agent metronidazole (Metronidazol, Sterling 
Products International Ltd., Blantyre, Malawi) before oral iodized oil administration. The 
choice of using albendazole and metronidazole for treating the respective parasitic 
infections was made in consultation with Ntcheu District Hospital who supplied the 
medication. Subjects without intestinal parasites (n = 30) or with mixed infestations (n = 
336) were not considered in this study. 
Ascaris lumbricoides was treated with a single dose of 400 mg albendazole. 
Hookworm cases were given a single dose of 400 mg albendazole daily for 3 consecutive 
days. Entamoeba histolytica cyst passers received 200 mg metronidazole 3 times a day for 
5 consecutive days. Per day, the first dose was taken under the supervision of a field 
assistant, the second dose was taken before leaving school under the supervision of the 
class teacher. For the third dose the subjects were given instructions to take the dose 
before going to bed. 
Two weeks after the onset of anti-parasitic therapy the subjects received 1 mL, 
490 mg iodine, Lipiodol Ultra Fluide (Laboratoire Guerbet, Aulnay-sous-Bois Cedex, 
France) orally using a dispenser (Englass Dispensing Devices, The English Glass Co. 
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Ltd., Leicester, England). The type of iodized oil used in this study comprised of a 
mixture of iodized ethyl esters. Subjects infested by less common parasites and those 
infested by two or more intestinal parasites received appropriate anti-parasitic treatment, 
as suggested by Ntcheu Hospital, but were not enroled in this study. One week after oral 
iodized oil administration two stool samples per treated subject were collected and 
examined in duplicate, as described above, to establish the cure rates of metronidazole 
and albendazole. 
Measurement of urinary iodine excretion was based on the concentration of iodine 
in casual urine samples as it was not possible to collect 24-h samples. Samples were 
collected between 0730 and 1100 at school under the supervision of field assistants. The 
iodine status of the subjects at baseline was determined from the average iodine 
concentration in urine samples collected on two consecutive days before iodized oil 
administration. Subsequent values were based on the average iodine concentration in 
casual urine samples collected on three consecutive days, per subject, during the 4th, 8th, 
20th, 40th and 44th week after oral iodized oil administration (13). 
Urinary analysis 
The urine samples, preserved with approximately 1 g thymol, were sent to the 
Department of Human and Animal Physiology of Wageningen Agricultural University 
where they were stored at -20° C prior to laboratory analysis. Iodine concentration in 
urine was assayed following alkaline digestion using the Sandell-Kolthoff reaction (14-16) 
adapted for use with a microtitre plate reader (Thermomax, Molecular Devices 
Corporation, Palo Alto CA, USA) coupled to a personal computer equipped with special 
software (Sofimax, Molecular Devices Corporation). The limit of detection or sensitivity 
was 0.04 jtmol/L. Recoveries of iodate and iodide were 100 % and 97 % respectively. 
All samples were assayed in duplicate and when measurements differed by < 10 % from 
their mean, the analysis was repeated in duplicate. The average of the duplicate 
measurements was used in the data analysis. Possible interference of the iodine assay by 
thiocyanate was examined by adding various amounts of potassium thiocyanate to a series 
of urine samples but the method was found to be insensitive to the presence of 
thiocyanate. 
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Statistical analysis 
The data of those subjects of whom at least one urinary iodine concentration was 
assessed during at least three weeks of urine collection were eligible for further statistical 
analysis. Average urinary iodine concentrations, per week of measurement, were 
calculated for the total group of treated subjects (n = 58) and untreated (n = 52) 
subjects. In addition, median urinary iodine concentrations were calculated per parasite 
group for treated and untreated subjects. 
The changes in iodine status over time after oral dosing with iodized oil can be 
described by a model (17): 
I(T,x) = («o +
 a ix)T- ( l !o+«i«, 
Where IT = Urinary iodine concentration at time t; 
T = Time (w) after dosing with iodized oil; 
x = (0,1) Variable containing information about untreated (0) and treated 
(1) intestinal parasitic infestation; 
a0 = Iodine retention for untreated subjects; 
a, = Iodine retention for treated subjects; 
ß0 = Rate of iodine elimination for untreated subjects; 
Ri = Rate of iodine elimination for treated subjects. 
The model was used to calculate iodine retention and elimination for untreated (a0 
and ß0) and treated (at and ß,) subjects general and per intestinal parasites (Entamoeba 
histolytica, Ascaris lumbricoides and hookworm). 
Given that I* is 0.40 pmol I/L urine which represents the level below which 
subjects are regarded as suffering from moderate iodine deficiency (18), the model-based 
duration of effectiveness in the different groups (T*) was calculated. 
Non-linear regression analysis was carried out to study the impact of intestinal 
parasites and anti-parasitic treatment on iodine retention, iodine elimination and the 
duration of effectiveness of orally administered iodized oil, using the model as described 
above, which describes the urinary iodine excretion patterns in each group. Asymptotic 
Student's t-values were computed to test for significance differences between the iodine 
retention for untreated (a0) and treated subjects (a0 + a,), and between iodine elimination 
for untreated (ß0) and treated subjects (ß0 + ßj). The goodness of fit of the model 
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(adjusted R2) was computed to determine the correlation of the urinary iodine excretion 
within each of the study groups. 
Results 
In Table 1, the prevalence of intestinal parasites in apparently healthy school 
children in Ntcheu District, and the iodine status per group is presented. Entamoeba 
histolytica, Ascaris lumbricoides, and hookworm were highly prevalent in the study 
population. The worm burden of Ascaris lumbricoides was low as all egg counts/g were 
less than 7000. For hookworm the egg count/g were distributed between 3000 and 8000 
indicating moderate worm burdens. No differences in age, sex and median urinary iodine 
concentration were found between the different study groups. The cure rates of 
albendazole and metronidazole were 96 and 89 % respectively. 
The median urinary iodine concentrations after oral dosing with iodized oil (during 
the 4th, 8th, 20th, 40th and 44th week) for the different treatment groups are given in 
Table 2. During the 4th week, all untreated subjects had significantly lower urinary 
iodine concentrations than the treated subjects (P < 0.001). The same was true for the 
untreated subjects in general and for those infested with Entamoeba histolytica and 
hookworm specifically compared to the treated subjects during the 8th week of follow up 
(P < 0.05). During week 20, 40 and 44 the median urinary iodine concentrations were 
comparable in all study groups although they remained slightly higher for those who had 
received anti-parasitic treatment. 
Table 1 Prevalence of intestinal parasites and median urinary iodine concentration 
of apparently healthy school children, Ntcheu District, Malawi (n = 484) 
No Entamoeba Ascaris Necator 
parasites histolytica lumbricoides americanus 
Mean age, y [SD] 
Prevalence of parasites, % 
9.5 [0.8] 
6.0 
9.4 [0.9] 
67.6 
9.5 [0.8] 
26.0 
9.4 [0.9] 
63.2 
Median urinary iodine 0.17 0.18 0.17 0.17 
concentration, jimol/L1 (0.12,0.26) (0.12,0.26) (0.11,0.26) (0.08,0.26) 
1
 25th and 75th percentile in parentheses. 
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In Table 3, the parameters for retention and elimination of iodine after oral 
iodized oil administration, which describe the urinary iodine excretion pattern, using the 
hyperbolic function, are given for the different study groups. The asymptotic Student's t 
values, given in Table 3, indicate a statistically significant improved retention of iodine 
for treating intestinal parasites in general. The model-based duration of effectiveness for 
untreated (T0*) and treated subjects (T,*) in general is 9.2 and 16.8 weeks respectively, 
the difference of 7.6 weeks being statistically significant (P < 0.001). Graphical 
representations of the urinary iodine excretion patterns for untreated and treated intestinal 
parasitic infestations in general, as described by the hyperbolic function, are presented in 
Figure 1. 
No difference in iodine retention and elimination was found between treated and 
Figure 1 Urinary iodine excretion (in natural logarithms), after oral iodized oil 
administration in apparently healthy school children treated and untreated for intestinal 
parasites before oral dosing with iodized oil, Ntcheu District, Malawi1 
.Q 0.1^ 
0 
1 T™ 
10 20 30 
Time.w 
40 50 
1
 For description of model, see text. I* is 0.40 ^mol/L, the level of urinary iodine 
concentration below which there is moderate iodine deficiency. 
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Figure 2 Urinary iodine excretion (in natural logarithms), after oral iodized oil 
administration in apparently healthy school children treated and untreated for Entamoeba 
histolytica before oral dosing with iodized oil, Ntcheu District, Malawi1 
^ 4.49 
o 
E 
c 
o 
c 
(_> 
C 
O 
0) 
c 
T3 O 
a 
c 
2.72-
1.64-
1-
0.61 
0.37-
0.22-
0.14 
\ 
0 
\ Treated 
20 30 
Time,w 
50 
1
 For description of model, see text. I" is 0.40 /xmol/L, the level of urinary iodine 
concentration below which there is moderate iodine deficiency. 
untreated Entamoeba histolytica cyst passers. Despite this result, which may be due to the 
limited number of observations, an adjusted R2 value of 0.24 was found for Entamoeba 
histolytica cyst passers meaning that the goodness of fit of the hyperbolic function for the 
urinary iodine excretion pattern within this group was high. This indicates that Entamoeba 
histolytica has a large effect on the efficacy of orally administered iodized oil. This notion 
is confirmed when looking at the model-based duration of effectiveness; for untreated and 
treated subjects, the duration of effectiveness is 2 w and 21 w respectively (P < 0.05) as 
can be seen in Table 3. Graphical representations of the urinary iodine excretion patterns 
for the untreated and treated Entamoeba histolytica cyst passers, as described by the 
model, are presented in Figure 2. 
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No significant differences were found in the retention and elimination of iodine 
between treated and untreated Ascaris lumbricoides and hookworm. However, both 
retention and elimination rate are slightly increased for treated subjects. Adjusted R2 
values were 0.15 and 0.09 for Ascaris lumbricoides and hookworm respectively indicating 
that a large variance in urinary iodine concentration confuses the urinary iodine excretion 
pattern as described by the model. 
Discussion and conclusions 
Intestinal parasitic infestations are an important cause of chronic diarrhoea in 
which fat absorption can be reduced by 50 % of normal (19). It may be expected that 
some intestinal parasites reduce the absorption of orally administered iodized oil. Their 
possible role in the malabsorption of iodized oil is biologically plausible as Ascaris 
lumbricoides has also been associated with the malabsorption of vitamin A (20-22). 
However, so far no studies have been described on the effect of intestinal parasites on the 
effectiveness of oral iodized oil administration for control and prevention of iodine 
deficiency. 
The prevalence of intestinal parasites found in the study population is in 
accordance with that reported in Malawi. As we did not recover worms after treatment of 
hookworm it was not possible to diagnose specific infections with Necator americanus. 
However, this species is the predominant hookworm found in Ntcheu District, Malawi, as 
reported by the District Hospital. 
All subjects who had received anti-parasitic treatment showed significantly higher 
urinary iodine concentrations during the 4th week after oral administration of iodized oil 
compared to those who were not treated. This indicates an improvement of iodized oil 
absorption after treating intestinal parasites in general. 
Entamoeba histolytica has a cosmopolitan distribution which occurs 
characteristically in endemic form. An infestation by this pathogenetic amoeba is 
characterized by acute and chronic phases (23). The infestation rate is low in young 
children, but in the school age group the incidence reaches that of the general population. 
In this study the subjects infested by this amoeba species were so-called chronic cyst 
passers without significant symptoms. We are aware of the growing view that what is 
currently called Entamoeba histolytica is in fact two species, one of which is invasive and 
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the other non-invasive (24). Unfortunately the cysts of the two species are 
indistinguishable by microscope. As we did not detect trophozoites containing blood 
corpuscles, to distinguish between the two species of Entamoeba histolytica, we cannot be 
certain which one we observed. Nevertheless, the vast impact of Entamoeba histolytica on 
the estimated duration of effectiveness of oral iodized oil administration is alarming; only 
two weeks for the untreated subjects. The fact that in this study no significant distinction 
was found in iodine retention between untreated and treated cyst passers may be due to 
the limited number of observations for the untreated Entamoeba histolytica cyst passers 
(n = 8) as urinary iodine concentration remains an index with a highly day to day 
variation. As Entamoeba histolytica is a parasite of the large bowl, and oils and fats 
(triacylglycerol esters) are absorbed from the small bowl, it remains unclear by what 
mechanism this parasite might be expected to impair the absorption of the ethyl esters of 
iodized fatty acids. A possible explanation may be that iodized ethyl esters are not, like 
triacylglycerols, absorbed from the small intestine, but for the large bowl. A general 
effect of this parasite may be that it stimulates bowl movement. In this case the increased 
passage time of the ethyl esters through the large bowl may not leave sufficient time for 
the absorption of the iodized ethyl esters thus affecting the availability of dose of iodine. 
It may be expected that the effectiveness of a type of iodized oil in which the iodized fatty 
acids are present as triacylglycerol esters will not be influenced by intestinal parasites of 
the large bowl. 
Ascaris lumbricoides and hookworm are common parasites of the small intestine of 
man and have a world-wide distribution. For subjects who had received anti-parasitic 
treatment the median urinary iodine concentrations, 4 weeks after oral iodized oil 
administration, were higher compared to those subjects who had not received anti-
parasitic therapy. This indicates that the absorption of iodized oil was improved for 
subjects who were treated for Ascaris lumbricoides and hookworm. Although the iodine 
retention was increased for treated subjects the iodine elimination rate was also increased 
which resulted in comparable durations of effectiveness between treated and untreated 
infestations. This result by itself disputes the need of a dose of 480 mg iodine for 
children. The dose of iodine can probably be reduced without affecting the duration of 
effectiveness. However, further research is needed to establish the optimal dose of iodine 
for oral iodized oil administration. 
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It may be possible that the effect of Ascaris Iwnbricoides on the absorption of 
iodized oil is underestimated in this study as the worm burdens were light ( < 7000 egg 
count/g) (21). In addition, the type of iodized oil which was used in this study, ethyl 
esters of iodized fatty acids, may not be affected by intestinal parasites of the small 
intestine. Further research is needed to study the effect of intestinal parasites of the small 
intestine on the efficacy of an oral dose of iodized oil which consists of triacylglycerol 
esters of fatty acids. 
Entamoeba histolytica cyst passers treated with metronidazole remained above 
iodine deficiency level (0.40 /jmol/L) for 21 weeks which exceeds the average duration of 
effectiveness of the type of oral iodized oil by far. This suggests an effect of 
metronidazole on the absorption of the iodized ethyl esters. It does not treat Entamoeba 
histolytica specifically as it is a very broad spectrum antimicrobial agent which acts 
against a wide range of anaerobic bacteria as well as intestinal protozoa. Bacterial 
overgrowth of the small intestine is common in children in developing countries which 
leads to deconjugation of bile salts and poor fat absorption in general (25). The observed 
increase in the efficacy of orally administered after metronidazole treatment may also be 
the result of treating bacterial overgrowth. 
Since no cases of Giardia duodenalis were found in the study population, it was 
not possible to study the impact of giardiasis on retention and the duration of effect of 
oral iodized oil administration. Giardia duodenalis, a flagellate with a world wide 
distribution, is one of the most important causes of chronic diarrhoea with impaired fat 
absorption in developing countries (26-28). It can be expected that Giardia duodenalis, 
like Entamoeba histolytica, greatly reduces the efficacy of oral iodized oil. Other studies 
will need to investigate the effect of giardiasis on the efficacy of oral iodized oil. 
From the results in this study it can be concluded that the duration of effectiveness 
of orally administered iodized oil is significantly reduced by intestinal parasitic 
infestations in general. In case of infestations by Entamoeba histolytica it would appear 
that anti-parasitic therapy is imperative when an oral iodized oil preparation consists of 
iodized ethyl esters since we found no effect of oral iodized oil on the urinary excretion 
of iodine in untreated subjects. Given the teratogenicity associated with metronidazole, its 
side effects, its cost and the practicability of treating everyone before administering 
iodized oil orally, it is unlikely to be acceptable. However, the impact of Entamoeba 
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histolytica may be overcome by using an iodized oil which contains triacylglycerol esters 
of iodized fatty acids. In this case more research is needed on the role of intestinal 
parasites of the small intestine on the effectiveness of this type of oral iodized oil. 
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5 Nutritional status and the efficacy of orally administered iodized 
oil for controlling iodine deficiency 
Carina A. Fumée, Clive E. West, Frits van der Haar and Joseph G.A.J. Hautvast1 
Abstract 
The relation between nutritional status and the efficacy of oral iodized oil for 
controlling iodine deficiency was studied in a randomized intervention study. No 
relationship was found between the efficacy of orally administered iodized oil and the 
initial height-for-age, weight-for-height and midupper-arm circumference. Children with a 
relatively large subcutaneous fat mass retained more iodine than subjects with little 
subcutaneous fat (P < 0.02) which resulted in a prolongation of the duration of 
effectiveness of 7.6 weeks. For goitrous subjects both retention and elimination of iodine 
were increased. The duration of effectiveness was approximately 15 weeks longer (P < 
0.05) for the goitrous subjects. Changes in height, weight, weight-for-height or 
subcutaneous fat mass were not related to the efficacy of oral iodized oil. A reduction in 
midupper-arm circumference prolonged the duration of effectiveness by 6 weeks (P < 
0.05). 
Introduction 
Studies on orally administered iodized oil for control of iodine deficiency have so 
far revealed large variations in its duration of effect (1-6). These large variations confuse 
the results of measurements for effective control of iodine deficiency using oral iodized 
oil. The study described here aims at contributing towards an understanding of the impact 
of the initial nutritional status, energy balance, iodine status and the initial size of the 
thyroid gland on the retention, elimination and the duration of effectiveness of orally 
administered iodized oil. Further, the effect of changes in nutritional status are 
considered. An understanding of the factors affecting absorption, retention and elimination 
of iodine after oral dosing with iodized oil may contribute to a more effective control of 
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iodine deficiency when oral iodized oil is the prophylactic measure of choice. 
Subjects and methods 
Subjects 
Subjects were selected from 8, 9, and 10-y-old school children (n = 502) 
attending four primary schools in Ntcheu District, Malawi, where goiter is highly 
prevalent. The schools were selected on the basis of having a sufficient number of pupils 
attending and on their accessibility as they were close to the main highway in Malawi 
which connects the Northern, Central and Southern Regions of the country. The study 
was approved by the Ethics Committee of the National Council for Medical Research of 
Malawi in 1989. Informed consent for each child was obtained before the start of the 
study from parents or guardians. As only apparently healthy subjects were considered 
suitable for entry into the study, all children were examined by a medical assistant from 
Ntcheu District Hospital. Children with significantly enlarged liver or spleen, indicative 
of disease which may interfere with fat or protein metabolism, or with a midupper-arm 
circumference < 15.5 cm, indicative of protein-energy malnutrition, were excluded from 
the study (n = 16). Stool samples were microscopically examined for intestinal parasite 
infestations and those subjects with intestinal parasites received appropriate anti-parasitic 
medication two weeks prior to receiving oral iodized oil. 
Anthropometry 
Weight, height, midupper-arm circumference and biceps, triceps, subscapular, and 
supra-iliaca skinfolds measurements were assessed as described by Jelliffe and Jelliffe, 
1989 (7) at two/three monthly intervals. In short, weighing was done on a electronic 
weighing scale, precise to the nearest 0.1 kg with a digital display which was frequently 
rechecked for accuracy using calibration weights. The subjects wore minimum clothing 
and no shoes. Height measurements were taken using a Microtoise, precise to the nearest 
0.1 cm, using a portable measuring board to ensure a vertical position. Midupper-arm 
circumference was taken on the upper left arm half way between the acromial process of 
the scapula and the olecranon process of the ulna using a flexible measuring tape which 
was checked for accuracy at regular intervals using a ruler. Four skinfolds measurements 
(biceps, triceps, subscapular and supra-iliaca) were taken twice on the left side of the 
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body using a Halpenden calliper (Holtain Ltd. Crymmych, UK) which was set at zero 
before each measuring session. Throughout the study all measurements were taken by the 
same person. Weight, height and midupper-arm circumference measurements were taken 
in duplicate, skinfolds were measured in triplicate at three monthly intervals. The average 
of the two measurements was used in the statistical analysis. During each measuring 
round a standardization test for all measurements was carried out with ten randomly 
selected subjects. Both precision and accuracy of all measurements were satisfactory at 
each measuring round. 
Study design 
This study is one of a number of studies on factors which may affect retention, 
elimination and effectiveness of oral iodized oil administration for control and prevention 
of iodine deficiency. 
A group of randomly selected subjects (n = 202) received 1 mL, 480 mg iodine, 
Lipiodol Ultra Fluide (Laboratoire Guerbet, Aulnay-sous-Bois Cedex, France) orally 
using a dispenser (Englass Dispensing Devices, The English Glass Co. Ltd., Leicester, 
England). Within this group, 37 randomly selected subjects received a carbohydrate-rich 
drink (Fantomalt, 100g in 100 mL of water; 1610 kJ, Nutricia, the Netherlands) over a 
period of 15 to 30 min prior to receiving Lipiodol UF. A placebo group (n = 35) 
received 1 mL neutral poppy-seed oil (Laboratoire Guerbet). The data of the remaining 
group of subjects are not considered in this study as they had received an alternative type 
of iodized oil, had only one type of intestinal parasites or had received a split dose of 
iodized oil. 
Measurement of urinary iodine excretion was based on the concentration of iodine 
in casual urine samples as it was not possible to collect 24-h samples. Samples were 
collected during morning hours at school under supervision of field assistants. The iodine 
status of the subjects at baseline was determined from the median values of the iodine 
concentration in urine samples collected on two consecutive days before iodized oil 
administration. Subsequent values were based on the median values of the iodine 
concentration in casual urine samples collected on three consecutive days during the 4th, 
8th, 20th, 40th and 44th week after oral iodized oil administration (8). 
The thyroid gland was graded by palpation as recommended by the World Health 
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Organization (9). For all subjects the goiter grading was done by the same person, before 
and 40 weeks after oral iodized administration. This person was not aware of the 
difference in the treatment schedules. Double checking was done by one of the authors 
who had no direct access to the treatment schedules and previous measurements. In case 
of doubt the lowest goiter grade was recorded. 
Urinary analysis 
The urine samples, preserved with approximately 1 g thymol, were sent to the 
Department of Human and Animal Physiology of Wageningen Agricultural University 
where they were stored at -20° C prior to laboratory analysis. Iodine concentration in 
urine was assayed following alkaline digestion using the Sandell-Kolthoff reaction (10-12) 
adapted for use with a microtitre plate reader (Thermomax, Molecular Devices 
Corporation, Palo Alto CA, USA) coupled to a personal computer equipped with special 
software (Sofimax, Molecular Devices Corporation). The limit of detection, sensitivity, 
was 0.04 /imol/L. Recoveries of iodate and iodide were 100 % and 97 % respectively. 
All samples were assayed in duplicate and when measurements differed by > 10 % from 
their mean, the analysis was repeated in duplicate. The average of the duplicate 
measurements was used in the data analysis. Possible interference of the iodine assay by 
thiocyanate was examined by adding various amounts of potassium thiocyanate to a series 
of urine samples but the method was found to be insensitive to the presence of 
thiocyanate. 
Statistical analysis 
For analysis only the data of those subjects with at least one urinary iodine 
concentration at 4 points of measurement were considered. Per group the median urinary 
iodine concentration was calculated per week of measurement using each individuals 
average urinary iodine concentration, calculated from the casual urine samples collected 
during that particular week. 
To distinguish between subjects with different height-for-age and weight-for-height 
characteristics, z-scores were calculated using the NCHS (National Center for Health 
Statistics) reference population (13). The standard deviation (SD) was used as cut-off 
point for the identification of the subjects. For weight, midupper-arm circumference and 
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the sum of skinfolds the actual group mean was calculated and the SD was used as cut-off 
point for identification. 
To study the effect of an increase or decrease in weight, weight-for-height, 
midupper-arm circumference and the sum of skinfolds the second measurement, taken two 
months after oral iodized oil administration was subtracted from the base-line 
measurement taken before oral dosing with iodized oil. The mean change was calculated 
per indicator and the SD was used as cut-off point for identification. 
The changes in urinary iodine concentrations over time after oral dosing with 
iodized oil can be described by the following equation (14): 
I(T,x) = (ao + a ^ T - * 6 0 ^ 
where, I = urinary iodine concentration (jumol/L); 
T = time (w) after oral dosing with iodized oil; 
x = nutritional indicator or second minus first measurement; 
a0 = iodine retention capacity of subjects with z-scores or measurements 
between -1 SD and +1 SD; 
»! = iodine retention capacity of subjects with z-scores or measurements 
smaller than -1 SD, a decrease in x (second minus first 
measurement < 0), goiter stage 0 or a negative energy balance; 
a2 = iodine retention capacity of subjects with z-scores or measurements 
greater than + 1 SD, an increase in x (second minus first 
measurement > 0), goiter stage > 0 or a positive energy balance; 
ß0 = iodine elimination rate of subjects with z-scores or measures 
between -1 SD and +1 SD in x; 
ß! = iodine elimination of subjects with z-scores or measurements smaller 
than -1 SD in x, a decrease in x (second minus first measurement 
< 0), goiter stage 0 or a negative energy balance; 
ß2 = iodine elimination rate of subjects with z-scores or measurements 
greater than + 1 SD, an increase in x (second minus first 
measurement > 0), goiter stage > 0 or a positive energy balance. 
The parameters a0, alt a2, ß0, ßi and ß2 were estimated using urinary iodine 
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concentrations for subjects with different nutritional characteristics; the parameters for the 
measures of the nutritional indicators, expressed in terms of z-scores of height-for-age 
and weight-for-height or weight, midupper-arm circumference and the sum of skinfolds 
distributed between -1 and +1 SD have been given subscript 0. Subscripts 1 and 2 
characterize the parameters for subjects in relation to the measures of the nutritional 
indicators less than -1 SD and greater than +1 SD respectively. 
Given estimates for a0, au a2, ß0, ß, and ß2 and values for I*, being the cut-off 
points indicating urinary iodine concentration values associated with the degree of the 
severity of iodine deficiency as suggested by WHO/UNICEF/ICCIDD (15), a model-
based duration of effectiveness can be calculated. In this study the model-based duration 
of effectiveness (T*) was assessed for I* = 0.40 jtmol/L, moderate iodine deficiency (15). 
Non-linear regression analysis was carried out to study the impact of the initial 
nutritional status, initial urinary iodine concentration, goiter, energy balance, and 
alterations in nutritional indicator values, based on the model as described above, to 
compare the urinary iodine excretion patterns in the groups with different nutritional 
characteristics. Asymptotic Student's t-values were computed to test the significance of 
differences between the parameters a0, a0 + ai an<^ ao + «2. and between ß0, ß0 + ßi 
and ß0 + ß2. The goodness of fit of the model (adjusted R2) was computed to determine 
the correlation of the urinary iodine excretion within each of the study groups. 
Results 
In Table 1 the mean weight, height, weight-for-height, midupper-arm 
circumference and sums of skinfolds are given as well as the median urinary iodine 
concentration and the total goiter percentages before and 40 weeks after oral dosing with 
either iodized oil or neutral poppy-seed oil. With regard to all variables considered, the 
study group and the placebo group were comparable before the onset of the study. After 
40 weeks the nutritional indicators in the study group and the placebo group were still 
comparable indicating no effect of iodine supplementation on these indicators. In the 
iodine supplemented groups the median urinary iodine concentration remained above 0.16 
/xmol/L, indicative of severe iodine deficiency, up to week 40. In the placebo group the 
urinary iodine concentration remained low throughout the study. Total goiter, was 
reduced from 62.9 % to 20.8 % in the iodized oil treated group and had increased from 
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Table 1 Nutritional status of the subjects at base-line and 40 weeks after receiving either 
oral iodized oil or neutral poppy-seed oil, Ntcheu, Malawi1 
n 
Energy balance, n 
Weight, kg 
Height, cm 
Weight / Height, kg/cm 
MUAC2, cm 
Sum of skinfolds, mm 
Urinary iodine 
concentration (/tmol/L)2 
Total goiter, % 
Iodized oil 
Base-line 
197 
35 
25.3 (3.6) 
126.2(7.1) 
0.20 (0.02) 
18.2 (1.4) 
20.8 (7.5) 
0.15 
[0.11,0.23] 
62.9 
40 w 
197 
35 
26.7 (4.0) 
129.6 (7.2) 
0.21 (0.02) 
18.1 (2.8) 
18.6 (4.4) 
0.32 
[0.16, 0.54] 
20.8 
Poppy-seed oil 
Base-line 
33 
25.2 (3.9) 
127.2 (6.4) 
0.20 (0.03) 
18.1 (1.0) 
19.8 (3.5) 
0.19 
[0.10, 0.54] 
60.0 
40 w 
33 
26.1 (3.3) 
130.1(6.5) 
0.20 (0.02) 
18.1 (1.1) 
18.3 (3.2) 
0.16 
[0.07, 0.30] 
65.7 
1
 Mean (SD). 
2
 Midupper-arm circumference. 
3
 Median [25th percentile, 75th percentile]. 
60.0 % to 65.7 % in the placebo group. After 40 weeks the median urinary iodine 
concentration in the iodize oil treated group had returned to base-line value and was again 
comparable to that in the placebo group. 
In Table 2 the relationship between nutritional indicators and parameters of iodine 
retention capacity and excretion is shown. An effect on both iodine retention (a) and 
elimination (ß) was observed for weight-for-height. The duration of effectiveness (T*) for 
children of low (< -1 SD) and high (> 1 SD) weight-for-height was 14.6 and 21.3 
weeks, respectively, but the difference was statistically only marginally significant (P = 
0.08). Subjects with a high sum of skinfolds (> 1 SD) retained more iodine (P < 0.02) 
than those with a low sum of skinfolds (> -1 SD) (a2 < a{) but there were no 
differences between their respective iodine elimination rates (ß, = ß2). 
The initial urinary iodine concentration had no effect on retention (a), elimination 
(ß) and the duration of effectiveness (Table 3). Both iodine retention (aj) and elimination 
(ß2) and hence duration of effectiveness were significantly increased in goitrous subjects 
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Table 2 The Statistical relationship between the initial nutritional status and the retention, 
elimination and duration of effectiveness of oral iodized oil, Ntcheu, Malawi1 
x, SD 
Z, SD 
« 0 
<*i 
« 2 
ßo 
ß. 
ß2 
R2 
Tt 
T2 
T2-T, 
Height-for-age 
-1.41, 1.07 
1.27 (4.33)2 
-0.23 (1.11) 
-0.04 (0.15) 
-0.03 (0.65) 
-0.11 (1.28) 
0.01 (0.06) 
0.15 
17.4 (8.19)2 
13.3 (6.58)2 
-4.1 (1.38) 
[0.162] 
Weight-for-height 
-0.24, 0.65 
0.93 (3.87)2 
-0.94 (2.02)3 
2.43 (2.48)3 
0.35 (5.09)2 
-0.28 (2.79)2 
0.42 (3.05)2 
0.17 
14.6 (7.71)2 
21.3 (6.05)2 
6.7 (1.73) 
[0.081] 
Midupper-arm 
18.14, 1.49 
7.22 (4.83)2 
-0.32 (3.73)2 
-0.30 (4.74)2 
2.25 (5.97)2 
-0.10 (4.41)2 
-0.09 (4.33)2 
0.17 
15.2 (10.05)2 
16.9 (6.93)2 
1.7 (0.58) 
[0.572] 
Sum of skinfolds 
20.42, 9.04 
2.71 (4.40)2 
-0.78 (2.19)3 
-0.02 (2.87)2 
0.58 (4.39)2 
-0.01 (0.59) 
-0.00 (0.32) 
0.18 
13.0 (10.06)2 
20.6 (6.87)2 
7.6 (2.35)3 
[0.018] 
1 1 (T,x) = (a0 + ah2) T(ß0 + ßl,2) (see text), x denotes the mean and Z denotes 
mean z-score; t-values is round parentheses, p-values in square parentheses. 
2
 Significant from 0 at 1 % level. 
3
 Significant from 0 at 5 % level. 
(P < 0.05 for T*). 
Positive energy balance, induced by oral energy supplementation, had no effect on 
retention, elimination of the iodine or the duration of effectiveness of oral iodized oil. 
Changes in weight, weight-for-height and subcutaneous fat mass did not effect 
retention, elimination or duration of effectiveness (results not shown). However, a 
decrease in midupper-arm circumference was found to increase iodine retention (<*! > 0), 
slow down elimination (fix < 0), and increase the duration of effectiveness from 12.2 to 
18.2 weeks (P < 0.05). 
Discussion and conclusions 
Weight-for-height, indicative of wasting, revealed only a marginally significant 
relationship with the efficacy of orally administered iodized oil at 5 % level (P = 0.08). 
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Table 3 The Statistical relationship between initial energy balance, goiter, urinary iodine 
concentration and alterations in midupper arm circumference (MUAC) and the retention, 
elimination and duration of effectiveness of oral iodized oil, Ntcheu, Malawi1 
0 0 
<*1 
« 2 
ßo 
ßl 
ß2 
R2 
T, 
T2 
T2-T, 
Energy balance 
1.52 (7.49)2 
0.57 (0.83) 
0.51 (11.19)2 
0.11 (0.91) 
0.17 
14.8 (12.01)2 
15.6 (6.22)2 
0.8 (0.31) 
[0.75] 
Goiter 
0.08(0.11) 
1.64 (4.93)2 
-0.15 (1.10) 
0.61 (8.85)2 
0.20 
10.6 (8.73)2 
25.4 (3.92)2 
14.7 (2.52)3 
[0.025] 
Urinary iodine 
1.47 (5.19)2 
-0.56 (1.02) 
0.48 (7.39)2 
-0.08 (0.45) 
0.14 
15.7 (7.97)2 
8.5 (2.07)3 
-7.2 (1.58) 
[0.115] 
Alterations in MUAC 
1.30 (5.86)2 
-0.98 (1.70) 
0.02(0.11) 
0.47 (8.57)2 
-0.11 (1.28) 
0.02 (0.54) 
0.16 
18.2 (7.94)2 
12.2 (7.85)2 
-6.0(2.14)' 
[0.031] 
1 1 (T,x) = (a0 + a u ) T"<ß0 + ßl,2) (see text); t-values is round parentheses, p-values 
in square parentheses. 
2
 Statistically significant at 1 % level, Students t-test. 
3
 Statistically significant at 5 % level, Students t-test. 
However, children with a relatively large subcutaneous fat mass were found to retain 
significantly more iodine than those with relatively little subcutaneous fat. Initial height, 
indicative of stunting, and the initial midupper-arm circumference (MUAC), indicative for 
energy-protein malnutrition when low, were not found to effect iodine retention, 
elimination or the duration of effectiveness of oral iodized oil. So far, little is known 
about possible storage sites of iodine, other than the thyroid, after oral iodized oil 
administration in human beings. Reichel et al (16) studied the absorption of Lipiodol in 
the lymph of cats using X-ray photographs and concluded that the uptake and metabolism 
of iodized oil from the gut was analogous to that of other dietary fats. Further, increased 
concentrations of iodine had been found in body fat of rabbits, rats and mice after oral 
administration of iodized oil and iodofat which is a preparation of sodium salts of iodized 
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fatty acids (17,18). From the results of our study it is apparent that significant quantities 
of iodine are stored in the subcutaneous fat and that it plays an important role in duration 
of effectiveness of orally administered iodized oil. 
Groen (19) reported increased iodine retention in adults gaining weight after oral 
administration of triacylglycerol esters of iodized fatty acids from poppy-seed oil. In our 
study using ethyl esters of iodized fatty acids from poppy-seed oil, weight gain or weight 
loss and changes in subcutaneous fat mass in children affect neither retention nor 
elimination of iodine after an oral dose. This may be due to the difference in chemical 
properties of the two types of iodized oil, their routes of absorption, storage sites and 
subsequent metabolic pathways. Of the glyceryl esters of iodized fatty acids used by 
Groen, 91 to 98 % was absorbed as neutral fat in normal persons. After absorption some 
of the iodized oil is oxidized and some is stored in the body. Absorption of ethyl esters of 
iodized fatty acids may be more rapid and may occur via a different mechanism and at a 
different site than neutral fat (triacylglycerol). This may account for the difference in the 
duration of effectiveness between the ethyl esters and the triacylglycerol esters of iodized 
fatty acids from poppy-seed oil reported in an earlier study (14). Once absorbed, ethyl 
esters may be less readily taken up by adipose tissue and become subject to more rapid 
oxidation. The iodine released will be taken up by the thyroid gland. The rate of iodine 
uptake by the thyroid will depend on the iodine status of the subject. 
The initial midupper-arm circumference was not found to play a role in iodine 
retention. However, a decrease in midupper-arm circumference during the study was 
observed to enhance significantly the duration of effectiveness of orally administered 
iodized oil significantly. A possible explanation for this finding may be that iodine is also 
stored in muscle tissue (approximately 50 % of the body mass) and that, when muscle is 
being broken down, iodine is slowly released into the plasma. From the plasma it can 
either be taken up by the thyroid or it can be excreted in the urine. In iodine-deficient 
subjects it may be expected that most of the iodine released by protein turnover would be 
taken up by the thyroid thus prolonging the duration of effectiveness. For those who do 
not need to utilize protein for energy supply the iodine would remains in the muscle tissue 
and will not become readily available to the thyroid. Gebre Medhin et al (personal 
communication) observed that subjects on a slimming diet, given iodized oil (ethyl esters 
of iodized fatty acids) demonstrated a longer duration of effectiveness of the orally 
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administered iodized oil than non-slimming subjects after receiving the iodized oil. In our 
study, general weight loss and the reduction of subcutaneous fat did not contribute to 
prolonging the duration of effectiveness, but a reduction in midupper-arm circumference 
did. The prolonged duration of effectiveness for slimming subjects as observed by Gebre 
Medhin et al may therefore also be the result of protein breakdown rather than the 
reduction in subcutaneous fat mass. 
In this study goitrous subjects retained more iodine after oral dosing with iodized 
oil than non-goitrous subjects which resulted in a difference in the duration of 
effectiveness being approximately 15 weeks. This increase in iodine uptake in goitrous 
subjects may be explained by an increase in the thyroidal iodine clearance rate which is 
known to occur when the thyroid gland mass is increased in order to compensate for 
iodine deficiency (20,21). In addition a significant increase in iodine elimination was 
observed in our study. Although no apparent negative side effects of the administered 
dose of iodine (480 mg) were observed or reported in our study it is reasonable to assume 
that the increased elimination of iodine may be the result of a mechanism in the thyroid 
gland to adjust its iodine content to its upper limit of iodine concentration in the process 
of size reduction (normalization) or overcoming mild hyperthyroidism. The initial urinary 
iodine concentration did not reveal an effect on iodine retention. 
From the results in this study it is apparent that subcutaneous fat tissue and muscle 
tissue are important for the storage of iodine after oral dosing with iodized oil. In the 
scope of increasing the duration of effectiveness of oral iodized oil administration, it is 
worthwhile to consider these findings when planning an iodine prophylaxis program using 
oral iodized oil. In developing countries, where the nutritional status of its people is 
known to fluctuate as a result of seasonality, oral iodized oil should be given at the end of 
the post-harvest season. 
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6 Methods for estimating the prevalence of iodine deficiency after 
oral dosing with iodized oil 
Carina A. Fumée, Frits van der Haar, Clive E. West and Joseph G.A.J. Hautvast 
Abstract 
A cumulative frequency distribution (CFD) of individually assessed durations of 
effectiveness of orally administered iodized oil can be described by either a concave-
shaped function or a sigmoid-shaped function. These functions describe the rates at which 
urinary iodine concentrations drop below a level associated with moderate iodine 
deficiency after oral iodized oil administration for subjects with different characteristics. 
For oil A (ethyl esters of iodized fatty acids) the CFD converged to unity (100%) faster 
than for oil B (triacylglycerol esters of iodized fatty acids). The number of non-
responders to oral iodized oil was significantly higher for oil A (11.1 %) compared to oil 
B (3.1 %). For 8, 9 and 10-y-old girls and for consumers of raw cassava the CFDs 
converged to unity faster than for boys of the same age and those who do not consumed 
raw cassava, respectively. 
Introduction 
Iodine deficiency is notoriously difficult to quantitate in an objective way. 
Therefore, it is hard to compare studies carried out at different places by different 
research investigators working in the field at different time intervals. Further, it is often 
impossible to study thyroid function, to closely define thyroid status and to obtain 
information on iodine intake. Consequently, iodine status and nutrition are generally 
evaluated by indirect indicators. Daily urinary iodine excretion is the most precise index 
of iodine status as the amount of iodine excreted in the urine corresponds to the level of 
iodine intake to maintain pre-existing iodine stores in the body (1). Iodine concentration is 
mostly measured in casual urine samples. Despite a large daily variation in iodine 
concentration as measured in these samples it remains an efficient index for evaluating 
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iodine supply, especially when an average iodine concentration can be calculated from 
two or more casual urine samples per individual taken on consecutive days (2). In a 
previous study we have shown that at group level the average retention of iodine, the 
iodine elimination rate and the duration of effectiveness can be calculated for orally 
administered iodized oil using a model (3). The parameters which describe this model are 
calculated from the urinary iodine concentrations of casual urine samples taken at regular 
intervals after oral iodized oil administration. A duration of effectiveness can be 
calculated per individual. The cumulative frequency distribution these individually 
assessed durations of effectiveness offers information about the rate at which the subjects 
become iodine deficient again, based on their urinary iodine concentration, after an oral 
dose of iodized oil. In this study methods are proposed to assess a continues relationship 
between duration of effectiveness and time. Subsequently, the rate at which subjects who 
have received either ethyl esters of iodized fatty acids from poppyseed oil or 
triacylglycerol esters of iodized fatty acids from poppyseed oil are compared. A 
distinction in the duration of effectiveness of the two types of oil had been established at 
group level in previous work (3). In addition, the effect of raw cassava consumption is 
studied because of its role in the etiology of iodine deficiency (4,5) and the impact of the 
male and female sex is considered as the prevalence of goiter was found to be unequally 
distributed over the two sexes (2). 
Materials and methods 
Subjects 
Apparently healthy school children, 8, 9, and 10-y-old from four schools in 
Ntcheu District, Malawi, were selected to participate in the study (n = 486). The study 
was approved by the Ethics Committee of the National Council for Medical Research of 
Malawi in 1989. Informed consent for each child was obtained from the parents or 
guardians before the study commenced. All children were examined by a medical assistant 
from Ntcheu District Hospital. Children with a significantly enlarged liver or spleen, 
indicating a clinical condition of disease which may interfere with fat or protein 
metabolism, or with a midupper-arm circumference < 15.5 cm, indicating energy-protein 
malnutrition, were excluded from the study. The thyroid gland was graded by palpation as 
recommended by the World Health Organization (6). For all subjects the goiter grading 
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was done by the same person, before and 10 months after oral iodized oil administration, 
who was not aware of the different treatment schedules. The grading was checked by one 
of the authors. In case of doubt the lowest goiter grade was recorded. 
Children with mixed intestinal parasites were treated with appropriate medication 
two weeks prior to receiving the iodized oil and admitted to this study. Subjects with 
single intestinal parasite infestations, who received a split dose of iodized oil, neutral 
poppy seed oil or a carbohydrate rich drink immediately prior to oral iodized oil 
administration are not considered in this study. From the remaining group of children (n 
= 244) the subjects were randomly allocated by age and sex to four different treatment 
groups. The control group (n = 197), received a single dose of 1 mL oil A (Lipiodol UF, 
490 mg iodine/mL, Laboratoire Guerbet, Aulnay-sous-Bois CEDEX, France) which is 
comprised of iodized fatty acids containing 490 mg iodine; an other group (n = 37) 
received a single dose of 1.25 mL oil B (Oriodol, 540 mg iodine/mL, Laboratoire 
Guerbet) which is comprised of triacylglycerol esters of iodized fatty acids containing 675 
mg iodine. The doses were administered orally using dispensers (Englass Dispensing 
Devices, The English Glass Co. Ltd., Leicester, England) delivering 1.0 mL (oil A) or 
1.25 mL(oilB). 
All subjects were visited in their homes (households) by two field workers to 
verify the date of birth, place of birth, sex and to obtain information on the consumption 
of raw cassava using a food frequency table and three standardized portion sizes of 
cassava root (75, 150 and 300 g). The main caretaker of the subject was asked whether 
the subject consumed raw cassava, what size the portions of cassava are on average and 
how often the subject consumed raw cassava. Those who ate raw cassava at regular 
intervals were classified as cassava consumers. All others were considered as non-
consumers. 
Study design 
The data of 234 subjects were eligible for analysis as they had received either a 
single dose of oil A or oil B, were free of intestinal parasites and data were available of 
urinary iodine concentrations from two or more periods of urine collection. In addition, 
information had to be available on the subjects cassava consumption habits. 
Measurement of urinary iodine excretion was based on the concentration of iodine 
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in casual urine samples as it was not possible to collect 24-h samples. Samples were 
collected during morning hours at school under supervision of field assistants. The iodine 
status per subject, at baseline, was determined from the average iodine concentration in 
urine samples collected on two consecutive days before iodized oil administration. 
Subsequent values were based on the average iodine concentration in urine samples 
collected on three consecutive days during the 4th, 8th, 20th, 40th and 44th week after 
oral iodized oil administration (2). 
Urinary analysis 
The urine samples, preserved with thymol, were sent to the Department of Human 
and Animal Physiology of Wageningen Agricultural University where they were stored 
at -20° C prior to laboratory analysis. Iodine concentration in urine was assayed 
following alkaline digestion using the Sandell-Kolthoff reaction (7-9) adapted for use with 
a micro titre plate reader (Thermomax, Molecular Devices Corporation, Palo Alto CA, 
USA) coupled to a personal computer equipped with special software (Sofimax, Molecular 
Devices Corporation). All samples were assayed in duplicate. When measurements 
differed by > 10% from their mean, the analysis was repeated. The precision and 
sensitivity of the procedure were 0.004 and 0.04 ^mol, respectively. The recoveries of 
standard iodate and iodide were 100 and 97 %. 
Statistical analysis 
Depletion of the iodine stores after oral iodized oil administration, measured as the 
urinary iodine concentration in casual urine samples taken at regular time intervals, can 
be described by a model (3): 
Ii(T) =
 aiT*\ 
where I = urinary iodine concentration; 
T = time in weeks; 
c*i = iodine retention capacity; 
ßj = iodine elimination rate; 
i = individual subject. 
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This can also be expressed as a log-linear relationship between urinary iodine 
concentration and time: 
In Ii(T) = In «; - ß; In T 
Given estimates ^ and b; of a; and ß; respectively, per subject, the individual duration of 
effectiveness Tj" can be calculated as follows: 
Tj' = (a;/r)1/bi 
Where I* is set at 0.40 fimol I/L urine representing the level below which subjects are 
regarded as suffering from moderate iodine deficiency (10). By assessing the model-based 
duration of effectiveness for each individual subject (Tj*) and sorting them in ascending 
order it is possible to plot a cumulative frequency distribution (CFD) of T' against time. 
Prior to statistical analysis a continuous relation is sought to describe the CFD of Tj* 
against time using standard techniques as described by Snedecor and Cochran (11). Such 
a continuous relationship facilitates the evaluation of the efficacy of oral iodized oil, 
based on the duration of effectiveness, in populations with different characteristics. 
Further, information can be obtained about the percentage of non-responders to oral 
iodized oil administration. In the subsequent analysis the efficacy of oil A and oil B are 
compared based on the rates at which the urinary iodine concentration of the subjects 
drop below 0.40 /imol/L subjects after oral dosing with iodized oil as calculated using the 
appropriate curve function for their respective CFD of Tj*. The same technique is used to 
compare the efficacy of oral iodized oil in boys and girls and in subjects who had or had 
not consumed raw cassava. 
Results 
Per study group the mean weight, height, midupper-arm circumference and the 
sum of four skinfolds with their respective standard deviations, the prevalence of total 
goiter and the median urinary iodine concentration at base-line have been given in Table 
1. All groups were comparable with regard to the nutritional indicators and urinary 
iodine concentration. For the girls the total goiter percentage was higher. There was no 
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difference in cassava consumption between the boys and girl. The boys and girls were 
equally distributed in all study groups. 
A concave shaped Inverse Polynomial (IP) curve (11): 
pCT) = [1 + a I (T- + ?)]-»; <r, y > 0 
was found to describe the CFD function of t;* against time in general (Figure 1) and for 
those who had received oil A specifically (Figure 2). However, the Gompertz-curve 
(sigmoid shaped): 
p(T*) = exp[-(r exp(-TT*)]; a, y > 0 
which is not symmetrical about the point of inflexion (11) was found to fit the CFD 
Figure 1 Incidence of iodine deficiency in total sample (n = 239) after oral dosing with 
iodized oil for controlling iodine deficiency for school-aged children, Ntcheu, Malawi 
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Figure 2 Incidence of iodine deficiency after oral dosing with iodized oil for controlling 
iodine deficiency for school aged children (n = 207) who had received oil A, Ntcheu, 
Malawi 
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Figure 3 Incidence of iodine deficiency after oral dosing with iodized oil for controlling 
iodine deficiency in school aged children (n = 32) who had received oil B, Ntcheu, 
Malawi 
10 20 30 40 50 60 70 80 90 100 
Time,w 
function best for those who had received oil B (Figure 3). 
The two curve functions, which fit their respective CFD, can be used to assess the 
prevalence of iodine deficiency at any time after oral dosing with iodized oil provided that 
the curve function fits the CFD properly. It can be expected that a CFD function which 
can be described by the Gompertz curve (oil B) is a sign of improved efficacy of oral 
iodized oil as it approaches unity (100 %) much slower than the IP curve for oil A does. 
The number of individuals in the sample, the number of non-responders, the type 
of curve that fits the CFD functions, the estimated values of a and 7 , a and 7 
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respectively, that describe shapes of the respective CFD functions for subjects with 
different characteristics have been summarized in Table 2. In addition, the corresponding 
squares of multiple correlation coefficients adjusted for the number of parameters 
estimated (R2) have been given for each curve that fits the CFD. The percentage of non-
responders to iodized oil was 10.4 % in the total group. For those subjects who had 
received oil B the percentage of non-responders was 3.1 % which is significantly lower 
than for those who had received oil A (11.1 %). For all other groups the percentage of 
non-responders were distributed between 9.2 and 11.8 %. 
In Table 3 the estimated times (w), per study group, are given at which 25 %, 50 
% and 75 % of the subjects have urinary iodine concentration below 0.40 /*mol/L again 
after oral dosing with iodized oil using the parameters a and y (Table 2) that describe the 
curve that fits each specific CFD of T' per study group best. 
The CFD of T" for subjects who had or who had not consumed raw cassava are 
both characterized by IP curves (Figures not shown). For subjects who had eaten cassava 
the IP curve converges to unity (100 %) faster than the IP curve for subjects who had not 
eaten cassava. This implies that the duration of effectiveness of oral iodized oil is reduced 
by the consumption of cassava. The cassava consumers reach a prevalence of 50 and 75 
% of urinary iodine concentrations below 0.40 jumol/L in a shorter period of time than 
those who did not consume raw cassava (Table 3). The difference in the duration of 
effectiveness being 2.9 and 10.3 weeks respectively. At group level cassava consumers 
were found to retain the iodine better than those who had not consumed cassava, but the 
elimination rate of iodine was also significantly increased for cassava consumers. The 
estimated mean durations of effectiveness of oral iodized oil at group level were 16.8 and 
21.0 weeks for cassava consumers and non-cassava consumers respectively (data not 
shown). 
The CFD of T;* and thus the IP curve for boys approaches 1 (100%) more slowly 
than for girls (Figure not shown). This indicates that the duration of effectiveness of 
iodized oil is longer for boys than for girls. For the girls a prevalence of 25, 50 and 75 
% of urinary iodine concentrations below 0.40 ^mol/L is reached in a shorter period of 
time than for the boys (Table 3) the difference in time being 2.4, 4.4 and 10.3 weeks 
respectively. At group level the boys were found to retain iodine significantly better than 
girls although their iodine elimination rate was slightly lower. The estimated mean Table 
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3 Estimates of the prevalence of iodine deficiency, as measured by urinary iodine 
concentration, after oral dosing with iodized oil for school aged children with different 
characteristics using cumulative frequency distributions of individually assessed durations 
of effectiveness1 
Time, in weeks, after oral dosing with iodized oil at which 
25, 50 and 75 % of the subjects have their urinary iodine 
concentration dropped below 0.40 jtmol/L 
25% 50% 75% 
All subjects 
Oil A 
OilB 
Cassava consumption 
No cassava 
consumption 
Boys 
Girls 
3.3(0.11) 
2.2 (0.10) 
31.4 (0.78) 
3.1 (0.13) 
3.4(0.19) 
4.5 (0.13) 
2.1 (0.19) 
15.2 (0.30) 
11.1 (0.25) 
53.2 (1.42) 
13.7 (0.32) 
16.6 (0.50) 
17.3 (0.31) 
12.9 (0.51) 
51.1 (1.04) 
37.7 (0.89) 
81.0 (2.41) 
45.8 (1.12) 
56.1 (1.74) 
55.4 (1.06) 
45.1 (1.83) 
1
 SE are given in parentheses. 
durations of effectiveness at group level were 20.6 and 16.8 weeks for boys and girls 
respectively (data not shown). 
Discussion and conclusions 
In this study we have shown that the cumulative frequency distribution (CFD) of 
the individually assessed duration of effectiveness of orally administered iodized oil can 
be described by either a concave function (IP-curve) or a sigmoid function (Gompertz-
curve). Both curves describe a relationship between the duration of effect and time, 
therefore they can be used to estimate the prevalence of iodine deficiency in a population 
at any time after oral dosing with iodized oil. From our data it appears that in case of a 
poor efficacy of orally administered iodized oil, as with oil A, the CFD of the 
individually assessed duration of effectiveness is concave shaped and is thus characterized 
by an IP curve. By an improved duration of effectiveness the CFD of the individually 
assessed duration of effectiveness takes the shape of the sigmoid function and it therefore 
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best characterized by the Gompertz curve as for oil B in this study. The difference in the 
efficacy of the two types of iodized oil was already established in a previous study (3). 
An oil type in which the iodized fatty acids are present as triacylglycerol esters (oil B) 
was found to be retained better than a type of oil in which the iodized fatty acids are 
present as ethyl esters (Chapter 3). We did not measure faecal excretion of iodine after 
oral dosing with iodized oil therefore we were unable to pronounce upon a distinction in 
the absorption of the two types of oil. However, the difference in retention of the two 
types of oil is likely due to a difference in the absorption mechanism of ethyl esters and 
triacylglycerol esters from the intestine although oil B contained 27 % more iodine. This 
notion is supported by the fact that in the present study the percentage of non-responders 
is much higher for those who had received oil A than for those who received oil B. 
For consumers of raw cassava an increased retention of iodine was observed. 
However, the elimination of iodine after oral dosing with iodized oil was also increased 
and to such an extent that the duration of effectiveness of oral iodized oil was shorter 
compared to those who did not consume raw cassava. In accordance with these findings 
the prevalence rate of iodine deficiency, based on urinary iodine concentration, was 
higher for those who consumed raw cassava. Cassava contains a cyanogenic glycoside 
linamarin, which is converted primarily to thiocyanate in the body. It is suggested that 
cassava consumption plays a direct role in causing endemic goiter as thiocyanate 
progressively reduces the thyroid function by accelerating the loss of iodine from the 
gland (4). In a previous study an increased retention of iodine after oral dosing with 
iodized oil was also observed for goitrous subjects (Chapter 5). Further, an increase was 
observed for the iodine elimination although this did not result in a decrease in the 
duration of effectiveness of the orally administered iodized oil as observed for consumers 
of raw cassava. For goiter the increased retention can be explained by an increased 
activity of the iodine trapping thyroid pump (12,13). The increased iodine elimination rate 
in goitrous subjects can be explained by a mechanism in the thyroid gland itself to 
eliminate excess iodine which was initially taken up as a result of the increased thyroidal 
iodine clearance rate (14). In the present study the prevalence of total goiter was the same 
for those who did and did not consume raw cassava which may be due to age. It may be 
expected that for those subjects who consume raw cassava the thyroidal iodine clearance 
rate is increased to compensate for the accelerated loss of iodine from the thyroid gland 
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due to presence of thiocyanate. This would explain the increased retention of iodine after 
oral dosing with iodized oil for the subjects who consumed raw cassava in this study. 
Although some iodine will be lost from the thyroid due to a mechanism in the thyroid 
gland itself to eliminate excess iodine, the increased iodine elimination rate for raw 
cassava consumers may primarily be explained by the impact of thiocyanate on the 
thyroid function. In this study we have shown that in populations where raw cassava is 
consumed oral iodized oil will need to be administered more frequently than in areas 
where no raw cassava is consumed in order to maintain an effective iodine prophylactic 
measure. 
The 8, 9, and 10-y-old girls in this study showed a significantly increased 
prevalence rate of iodine deficiency after oral dosing with iodized oil compared to the 
boys of the same age group in this study. In this study more girls were found to suffer 
from goiter than boys. With regard to the results of a previous study (Chapter 5), in 
which the duration of effectiveness of oral iodized oil was increased for goitrous subjects, 
it was expected that the prevalence rate of iodine deficiency after oral iodized oil 
administration would have been lower for girls than for boys. However, the opposite was 
observed and may possibly be explained by age-related changes in thyroid hormone 
production (T4 and T3) and changes in the concentration of plasma proteins that carry the 
thyroid hormones in the plasma. Thyroxine-binding globulin (TBG), T4 and T3 have been 
found to drop slightly between 1 and 15 years (15), and thyroxine-binding prealbumin 
(TBPA) has been found to increase during this period of life (16,17). Further, estrogens 
have been found to increase the serum concentrations of TBG which results in an increase 
in serum total thyroxine and in a decrease of T4 and the fractional turnover of this 
hormone (18-20). Opposite effects have been observed for androgenic hormones (18). It 
may be possible that the rate of age-related changes in thyroid hormone production and 
their availability are different for 8 to 10 years old boys and girls. However, we did not 
collect blood samples in this study to investigate the proposed explanations for the 
difference in efficacy of oral iodized oil between boys and girls. Further research, using 
appropriate indicators, is needed to obtain information on the role of hormones in the 
effectiveness of iodine prophylaxis. 
With a minimum of three observation per individual it is possible to compare the 
efficacy of oral iodized oil, measured as the decline of urinary iodine concentration in 
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casual urine samples with time (3). It may be worthwhile to reconsider studies on the 
effectiveness of oral iodized oil which have been carried out in the past in order to make 
them comparable. Using the models as proposed in this paper it is now possible to 
estimate the prevalence of iodine deficiency after oral dosing with iodized oil. They will 
be helpful for evaluating iodine supplementation programs using oral iodized oil. 
Knowledge about the impact of factors that influence the efficacy of oral iodized oil will 
contribute to identifying people at risk for iodine deficiency despite prophylactic measures 
taken. An additional advantage of the methods proposed for estimating the efficacy of oral 
iodized oil is that those people who do not respond to oral iodized oil, in terms of 
adequate urinary iodine concentrations, can be identified. For research purposes this 
group may be useful in providing additional information on factors that influence the 
efficacy of oral iodized oil. 
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7 General discussion 
Endemic goiter is easy to prevent. For developed countries and a number of 
developing countries this confident remark has been fully justified by subsequent 
experience. Many countries have been using prophylactic iodine for quite some time and 
the incidence of iodine deficiency disorders has notably declined in these countries. 
Despite available and feasible methods to combat iodine deficiency, using mainly iodized 
salt or iodized oil, approximately 1,000 million people, of which the majority reside in 
developing countries, receive insufficient iodine and suffer from its consequences (1). 
Presently most countries have met political agreement on implementing iodization 
programmes and are in the process of planning them. Ideally the method of choice for 
controlling iodine deficiency is salt iodization. This method is justified when the 
production or import of high quality iodized salt is centralized and liable to quality 
control. Furthermore, the networks for commercial salt distribution should be extensive 
and the price of iodized salt should be cheap. Many developing countries will have to 
tackle technical, geographical or political problems before they can successfully 
implement iodized salt programmes (2). As long as salt cannot be used as a fortification 
vehicle, oral iodized oil is ideally suited for immediately attacking the problem of IDD. 
Iodized oil can be given either by injection or orally. The duration of effectiveness 
of injected iodized oil exceeds that of oral iodized oil by far and may thus appear to be 
the most convenient and effective method for iodized oil administration. However, there 
are a number of shortcomings attached to injecting iodized oil. Although the chances for 
local inflammatory reaction at the injection site are trivial, it is a painful experience to 
receive the iodized oil intramuscularly. In order to minimize the complications associated 
with injecting the medical team should be thoroughly trained in aseptic techniques and 
skills. To diminish the chances of spreading highly infections diseases either disposable 
syringes and needles are needed or equipment should be available to ensure proper 
sterilization of the instruments. Fielding the injection team which includes salaries, food, 
lodging and transport will greatly contribute to the additional costs of an iodized oil 
injection program. Against the rather high expenses are the benefits of a procedure which 
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may protect the population for 3 to 5 years. 
Oral iodized oil, either as capsules or by using a dispenser, can be administered by 
any responsible person such as a primary health care worker or a school teacher. Besides 
the cost of iodized oil, import expenses, if any, and transportation, if an existing 
distribution network of medical goods does not exist, the expenses of an oral iodized oil 
program are substantially reduced. Despite a high variability in the duration of 
effectiveness (3-8), oral iodized oil has been winning ground since 1974. 
It is quite complicated and often impossible to obtain data on the actual iodine 
intake in most populations. For most nutrients the intake can be calculated using food 
composition tables. However, the iodine content of food and water is know to vary to 
such an extent that this method does not apply to its intake. Therefore, iodine status is 
often evaluated by indirect indices of which daily urinary iodine excretion is considered 
the most precise (9). As it is often very difficult to obtain accurate collection of 24-h 
urine samples it has been proposed that the ratio between the concentration of iodine and 
creatinine in casual urine samples be used to assess the iodine supply of populations (10-
12). The value of this ratio rests upon the assumption of a constant excretion of creatinine 
each day. However, in a recent study, carried out among Malawian school children with 
a median urinary iodine concentration of 0.16 /xmol/L, we observed large inter and intra 
individual variations in daily urinary creatinine concentration. Furthermore, the ratio 
between urinary iodine and creatinine correlated significantly with the creatinine 
excretion. Thus we have concluded that the iodine-creatinine ratio in casual urine samples 
is an unsuitable indicator for evaluating iodine status (Chapter 2 of this dissertation). 
Despite a high variation in daily iodine excretion the assessment of iodine concentration in 
causal urine samples remains a valuable method to evaluate iodine status. We have 
suggested that calculating an average iodine concentration of casual urine samples 
collected on consecutive days per individual enhances the precision of this index. 
The efficacy of oral iodized oil is determined as a combination of the retention of 
iodine in the body and the rate of iodine excretion in the urine. A model can be used to 
describe the urinary iodine excretion pattern over time after oral iodized oil administration 
thus allowing for the assessment of the duration of effectiveness and to study factors 
which may affect the retention and elimination of iodine (Chapter 3 of this dissertation). 
Cumulative frequency distributions of individually assessed durations of 
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effectiveness very conveniently describe the prevalence rate of iodine deficiency, based on 
urinary iodine concentrations, after oral iodized oil adminstration. Models can be used to 
describe these cumulative frequency distributions which may be very useful when 
evaluating oral iodized oil programmes for controlling iodine deficiency (Chapter 6 of this 
dissertation). An additional advantage is that information can be obtained on the number 
of non-responders. For research purposes this groups of non-responders may be useful in 
providing more information on factors that influence the efficacy of orally administered 
iodized oil 
In general oral iodized oil has been used without consideration of factors that may 
affect the absorption of iodized oil and the retention and elimination of iodine. From 
experience it is clear that the efficacy of oral iodized oil often leaves much to be desired. 
However, it must be kept in mind that the studies on the effectiveness of oral iodized oil 
have been carried out by different investigators at different geographical locations using 
different methods, indices and time schedules. This makes it impossible to draw a 
univocal conclusion on the effectiveness of oral iodized oil. 
In the study described in Chapter 3 we have shown that a single dose of an iodized 
oil in which the iodized fatty acids are present as triacylglycerol esters (675 mg iodine) 
has a duration of effectiveness of approximately one year whereas the duration of 
effectiveness of iodized oil (490 mg iodine) which consists of a mixture of ethyl esters of 
iodized fatty acids, lasted only 3-4 months. The former, which is cheaper to produce, is 
more viscous than the latter but quite suitable for oral use both as capsules and from a 
dispenser. 
From the results of our study on the impact of intestinal parasites we found that 
the effectiveness of iodized oil (ethyl esters of iodized fatty acids) was greatly improved 
by treating these infestations. For Entamoeba histolytica it appears that anti-parasitic 
therapy is imperative when iodized oil is administered orally since we found no effect of 
iodized oil in untreated subjects (Chapter 4 of this dissertation). This observation is 
almost certain due to a decreased absorption but systemic factors may also be involved. 
The question remains by which mechanism Entamoeba histolytica, a parasite of the colon, 
affects the absorption of the iodized oil since oil and fats, in general, are absorbed from 
the small intestine. Maybe ethyl esters, unlike triacylglycerol esters, are not absorbed 
from the small intestine but from the colon. In this case the influence of Entamoeba 
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histolytica may be overcome by giving an iodized oil preparation which consists of 
triacylglycerol esters of iodized fatty acids. However, more research is needed on the role 
of intestinal parasites of the small intestine on the effectiveness of such a type of iodized 
oil. This work should be extended to studies on the effectiveness of oral preparations of 
vitamin A. 
Children with a relatively large amount of subcutaneous fat were found to retain 
the iodine from orally administered iodized oil better than those with little subcutaneous 
fat. Height-for-age, weight-for-height and midupper-arm circumference have no effect on 
either retention or elimination of iodine resulting in a significantly altered duration of 
effectiveness of oral iodized oil. No adverse effects were found for dramatic changes in 
nutritional status. In fact, a reduction in midupper-arm circumference was observed to 
increase the duration of effectiveness of iodized oil. From our study it appears that both 
fat and muscle tissue play an important role in the efficacy of orally administered iodized 
oil. In the scope of increasing the efficacy of oral iodized oil it is worthwhile to plan its 
distribution during that part of the year in which the people are relatively well fed. This 
in case the nutritional status of a population is liable to seasonal fluctuation. 
Goitrous subjects were found to retain more iodine than non-goitrous subjects 
(Chapter 5 of this dissertation). This observation may be explained by the increased 
activity of the iodine pump which is known to occur when the thyroid is enlarged as a 
result of iodine deficiency (9). The partial autonomy of iodine trapping probably accounts 
for the persistent high uptake of iodine in human goiters after the administration of iodine 
supplements in general. The increase in iodine elimination in goitrous subjects may be the 
result of a intrathyroid mechanism to adjust its iodine content to its upper limit of iodine 
content. 
In areas where cassava is consumed raw it may be necessary to plan a more 
frequent distribution of oral iodized oil as we found the prevalence rate of iodine 
deficiency after oral iodized oil administration to be higher for subject who had consumed 
cassava (Chapter 6 of this dissertation). Only the impact of raw cassava consumption was 
studied, but similar effects may be expected when other goitrogenetic factors are present 
(Chapter 1 of this dissertation). Planners of oral iodized oil programs should be aware of 
the impact of goitrogenetic substances on the duration of effectiveness. 
In our study we also observed a statistically significant difference in the duration 
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of effectiveness of oral iodized oil between the old boys and girls. Further research, using 
appropriate blood parameters, is needed to explain this finding which indicates that girls, 
even when young, may need to receive oral iodized oil more frequently than boys. 
Recommendations for the use of oral iodized oil 
1. Oral iodized oil is extremely useful as an interim measure and in for controlling 
iodine deficiency as an interim measure until sufficient iodized salt is available to 
the whole population. 
2. Oral iodized oil should consist of triacylglycerols of iodized fatty acids rather than 
ethyl esters of iodized fatty acids. 
3. Oral iodized oil should be provided on an annual basis. 
4. Oral iodized oil should be given towards the end of the post-harvest season. For 
Malawi this is in October. 
5. The urinary iodine/creatinine ration is not an appropriate indicator to measure 
iodine status. 
6. The median rather than the mean urinary iodine concentration should be 
considered when assessing iodine status at population level. 
7. The evaluation of oral iodized oil programs can be improved by using the methods 
proposed in this dissertation. 
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Summary 
Iodine deficiency exists in areas where the soil has been depleted of iodine and the 
diet of the population consists predominatly of locally grown foods. Salt iodization is an 
inexpensive, highly effective means for preventing iodine deficiency. However, delays in 
achieving effective salt iodization in areas where iodine deficiency requires immediate 
attention demand an intermediate measure such as iodized oil given either by 
intramuscular injection or orally. Administration of iodized oil orally has practical 
advantages over intramuscular injections and has been used increasingly since 1974. 
However, the duration of effectiveness for orally administered iodized oil is much 
shorter, ranging from 6 months to two years, than for injected iodized oil. 
The general aim of the studies described in this dissertation is to improve the 
effectiveness of oral administration of iodized oil in the controlling iodine deficiency. The 
specific aims are (1) to compare the duration of effectiveness of two types of oral iodized 
oil each containing the same dose of iodine given as a single dose. One type of oil (oil A) 
was initially developed for intramuscular injection and consisted of ethyl esters of iodized 
fatty acids. The second type of iodized oil (oil B) consisted of triacylglycerol esters of 
iodized fatty acids. (2) To compare the effect of splitting the dose of oil A into two equal 
portions and giving them on two consecutive days to the efficacy of the single dose of oil 
A; (3) to study the impact of treating intestinal parasitic infestations on the efficacy of 
orally administered iodized oil and; (4) to determine whether nutritional status, sex, 
energy balance and the consumption of raw cassava play a role in the retention and the 
elimination rate of iodine after oral dosing with iodized oil. In addition, the 
appropriateness of using the urinary iodine-creatinine ratio as an indicator for the iodine 
status was considered as all results are based on urinary iodine concentrations of casual 
urine samples. Further, methods are proposed to describe the urinary iodine excretion 
pattern over time after oral dosing with iodized oil. 
The studies were carried out in Ntcheu District, Malawi, with 8, 9, and 10-y-old 
school children. All children were medically examined before the onset of the study, their 
thyroid gland was graded, the urinary iodine and creatinine concentration were 
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determined and weight, height, midupper-arm circumference and four skinfolds were 
measured. In addition, stool samples were examined microscopically for the presence of 
intestinal parasites. Those children with single intestinal parasitic infestations of either 
Entamoeba histolytica, Ascaris lumbricoides or hookworm were randomly selected to 
either receive anti-parasitic treatment either before or after oral dosing with iodized oil. 
All children with mixed infestations received anti-parasitic treatment before receiving 
iodized oil. These children were randomly allocated to receive either a single dose of oil 
A (490 mg iodine) or oil B (675 mg iodine), a split dose of oil A (2 x 245 iodine), a 
carbohydrate-rich drink immediately prior to receiving oil A, or neutral poppy seed oil 
(placebo). For follow up, anthropometric measurements were taken at two/three months 
intervals and their urinary iodine concentration was measured in three causal urine 
samples each taken on three consecutive days during the 4th, 8th, 20th, 40th and 44th w 
after oral dosing with iodized oil. All subjects were visited at their homes to verify the 
date of birth, sex and whether or not they consumed raw cassava. 
All results are based on urinary iodine concentrations in casual urine samples. Due 
to large variations in day-to-day urinary iodine excretion it is often related to urinary 
creatinine. The inappropriateness of relating urinary iodine to urinary creatinine to correct 
for the large day to day variation in urinary iodine output was established in the study 
described in Chapter 2. In this study large inter and intra individual variations were 
observed for both the creatinine and iodine concentrations in two casual urine samples 
collected on consecutive days. Furthermore, the urinary iodine/creatinine ratio correlated 
significantly with the creatinine concentration. If creatinine were a suitable parameter to 
correct for variations in iodine excretion, no correlation would be expected. From these 
observations we concluded that the iodine/creatinine ratio in casual urine samples is an 
unsuitable indicator for evaluating iodine status. To compensate for the day-to-day 
variations in iodine excretion we suggest that an average iodine concentration be 
calculated from two or more casual urine samples each taken consecutive days. 
Urinary iodine concentration reflects the mutual effects of the physiological 
mechanisms involved in iodine retention and elimination. In Chapter 3 a model is 
proposed which describes the urinary iodine excretion pattern, after oral iodized oil 
administration. In this model the efficacy of oral iodized oil is determined by the retention 
of iodine and its elimination rate. Subsequently, a duration of effect can be assessed 
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given a urinary iodine concentration of 0.40 /imol/L associated with moderate iodine 
deficiency (UNICEF/WHO/ICCIDD). The parameters, retention capacity and rate of 
elimination, that describe the model, were compared for subjects who had received either 
a single or split dose of oil A or a single dose of oil B. Compared to a single dose of oil 
A, the iodine retention of oil B was significantly higher. Although the iodine elimination 
rate was also increased for oil B the duration of effectiveness was significantly improved. 
The efficacy of splitting the dose of oil A into two equal amounts given on consecutive 
days did not improve compared to that of a single dose of oil A. The assessed duration of 
effectiveness was estimated to be 13.7, 9.9 and 55.2 weeks for a single dose of iodized 
oil A, a split-dose of oil A, and a single dose of iodized oil B, respectively. From this 
study we conclude that a single dose of oil type B, which consists of triacylglycerol esters 
of fatty acids, is much more effective compared to a single dose of oil A. Therefore oil B 
should be used for controlling iodine deficiency rather than oil A. 
The effect of treating intestinal parasites (Entamoeba histolytica (cyst passers), 
Ascaris lumbricoides and hookworm) in general and for each parasite specifically on the 
efficacy of orally administered iodized oil type A for controlling iodine deficiency has 
been described in Chapter 4. Treating intestinal parasitic infestations in general increased 
the duration of effectiveness of oral iodized oil with approximately 2 months. Treating 
Entamoeba histolytica specifically improved the duration of effectiveness from 2.0 to 21.0 
weeks (p < 0.05). In fact, it appears that the absorption of iodized oil is greatly 
disturbed for Entamoeba histolytica cysts passers. Entamoeba histolytica is a parasite of 
the large bowl, and fats and oil are absorbed from the small intestine. A possible 
explanation for the observed effect of this amoeba may be that ethyl esters of fatty acids 
are not absorbed from the small intestine from the colon. Therefore, the problem of 
decreased absorption may be overcome be giving an iodized oil preparation in which the 
fatty acids are present as triacylglycerol esters. In this case the impact of intestinal 
parasites of the small intestine such as Ascaris lumbricoides and hookworm will need to 
be reconsidered. 
The relation between nutritional status and the efficacy of oral iodized oil for 
controlling iodine deficiency was established in Chapter 5. Children with a relatively high 
sum of skinfolds, indicative of a relatively large subcutaneous fat mass, were found to 
retain more iodine than subjects with little subcutaneous fat. The duration of effectiveness 
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was increased by approximately 8 weeks for those with a high sum of skinfolds compared 
to those with a low sum of skinfolds. Although the initial midupper-arm circumference, 
indicative of protein-energy status, revealed no effect on the efficacy of orally 
administered iodized oil, a reduction in midupper-arm circumference prolonged the 
duration of effectiveness. This observation suggests that iodine is also stored in muscle 
tissue. For goitrous subjects both retention and elimination of iodine were significantly 
increased. The duration of effectiveness was approximately 4 months longer for the 
goitrous subjects compared to those without goiter. 
In Chapter 6 methods are proposed to assess the prevalence rate of iodine 
deficiency and the number of non-responders. In this study, frequency distributions of 
individually assessed durations of effectiveness, using urinary iodine concentrations, after 
oral iodized oil administration are considered for subjects with different characteristics. 
These methods were used to compare the efficacy of the two types of oral iodized oil and 
to compare the efficacy for boys and girls and for those who did or did not consume raw 
cassava. The prevalence rate for subjects who had received oil A increased faster than for 
those who had received oil B. The number of non-responders to oral iodized oil was 
lower for oil B (3.1 %) than for oil A (11.1 %). The prevalence of iodine deficiency 
increased faster for girls and for consumers of raw cassava than for boys and those who 
did not consumed raw cassava, respectively. 
In Chapter 7, the results and conclusions are discussed and a number of 
recommendations to improve the efficacy of oral iodized oil and to facilitate its evaluation 
are given. In short, oral iodized oil is a suitable prophylactic measure until iodized salt is 
readily available. However, the preparation should consist of triacylglycerols of iodized 
fatty acids and is preferably given at the end of the post-harvest season on an annual 
basis. In case of limited sources girls should have priority in receiving the iodized oil. 
For research purposes the median urinary iodine concentration should be 
considered rather than its mean. To correct for the highly variable output of iodine in the 
urine an average urinary iodine concentration, assessed in two or more casual urine 
sample taken on consecutive days per person, can be calculated. A hyperbolic function 
describes the urinary iodine excretion over time after oral dosing with iodized oil and 
requires a minimum of three observations at different time points for a relatively small 
number of subjects. Information on the prevalence rate of iodine deficiency and the 
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percentage of non-responders, based on urinary iodine concentrations, can be obtained 
using cumulative frequency distributions of individually assessed durations of 
effectiveness. 
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Samenvatting 
Een tekort aan jodium in het menselijk lichaam komt voor in gebieden waar geen 
jodium meer in de bodem voorkomt en waar de bevolking hoofdzakelijk van lokaal 
verbouwde produkten leeft. De meest bekende aandoening ten gevolge van jodiumgebrek 
is een zwelling van de schildklier die 2ichtbaar is in de hals. Dit wordt krop of struma 
genoemd. Naast krop kan een tekort aan jodium het risico op miskramen, 
zuigelingesterfte en aangeboren afwijkingen verhogen. De ernstigste aangeboren afwijking 
is cretinisme (dwerggroei), dat gepaard gaat met doofstomheid, arm- en 
beenverlammingen en idiotie. De ernst van de lichamelijke en/of geestelijke 
onderontwikkeling is afhankelijk van de mate van jodiumgebrek. 
Jodium deficiëntie kan gemakkelijk worden voorkomen door het gebruik van 
gejodeerd zout. In veel Derde Wereld landen is echter de verkrijgbaarheid van gejodeerd 
zout echter (nog) niet gegarandeerd. Ondanks dat er op het ogenblik overal ter wereld 
maatregelen worden getroffen voor de produktie van gejodeerd zout, blijft het de vraag of 
men daadwerkelijk op korte termijn hierover zal kunnen beschikken. Zolang de produktie 
en/of distributie van gejodeerd zout onvoldoende is, zullen andere middelen ter hand 
genomen moeten worden om dit gebrek te bestrijden. Het gebruik van gejodeerde olie is 
een goed alternatief en is reeds op grote schaal toegepast. Vroeger werd gejodeerde olie 
geïnjecteerd; een pijnlijke, kostbare, maar zeer effectieve maatregel die een paar jaar 
bescherming biedt tegen jodiumdeficiëntie. Later werd deze olie oraal toegediend in de 
vorm van capsules. Ondanks een veel kortere effectiviteitsduur werd deze methode van 
jodiumdeficiëntie-bestrijding populair omdat het goedkoper, veiliger en gemakkerlijker is 
dan injecteren. 
De studies beschreven in dit proefschrift, trachten inzicht te krijgen in de faktoren 
die mogelijk van invloed zijn op de effectiviteit van oraal toegediende gejodeerde olie. 
De specifieke onderzoeksdoelstellingen waren (1) het vergelijken van de 
effectiviteit van twee typen gejodeerde olie te vergelijken waarvan type A ethylesters van 
gejodeerde vetzuren bevat en type B triacylglycerolesters van gejodeerde vetzuren. Beide 
olieën zijn op basis van papaverzaad en bevatte ongeveer evenveel jodium per dosis; (2) 
het vergelijken van de effectiviteit van olie A wanneer deze als enkele dosis of in twee 
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keer de helft geven wordt op twee opeenvolgende dagen; (3) om de invloed van 
darmparasieten op de effectiviteit van oraal toegediende olie A vast te stellen; (4) om na 
te gaan of voedingsstatus, energie balans, het hebben van een vergrote schildklier en het 
consumeren van rauwe cassave van invloed zijn op de retentie en/of de 
uitscheidingssnelheid van jodium na orale toediening van gejodeerde olie A, en of bij 
jongens en meisjes verschillen optreden. 
Het onderzoek vond plaats in het district Ntcheu in Malawi. De proefpersonen 
waren 8 tot 10 jaar oude schoolkinderen afkomstig van 4 lagere scholen. Voor 
toediending van de gejodeerde olie werden alle kinderen medisch onderzocht. Verder 
werden de grootte van hun schildklier vastgesteld, de jodium en creatinine concentraties 
werden in twee urine monsters bepaald, en gewicht, lengte, middenbovenarmomvang en 
de dikte van 4 huidplooien (biceps, triceps, subscapula en supra-iliaca) werden gemeten. 
Kinderen met een vergrote lever, een vergrootte milt of een middenbovenarmomvang 
kleiner dan 15,5 cm werden niet in het onderzoek opgenomen. Alle proefpersonen werden 
onderzocht op darmparasieten. Een kleine groep kinderen met slechts één soort 
darmparasiet werd pas na toediening van de gejodeerde olie (type A) behandeld tegen de 
soort darmparasiet. Alle andere kinderen werden, indien nodig, tegen hun darmparasieten 
behandeld twee weken vóór dat ze gejodeerde olie kregen en werden ingedeeld in 
verschillende behandelingsgroepen (olie A met 490 mg jodium, olie B met 675 mg 
jodium, 2 keer de helft van olie A op twee opeenvolgende dagen, een energie-rijk drankje 
vlak voor de toediening van olie A, of neutrale papaverzaad olie). Na toediening van de 
gejodeerde olie werden, met tussenpozen van 2/3 maanden, de anthropometrische 
metingen herhaald. Gedurende de 4de, 8ste, 20ste, 40ste en 44ste week werden per 
persoon drie urine monsters verzameld op drie opeenvolgende dagen. Van ieder monster 
werd de jodiumconcentratie bepaald. 
Alle resultaten in dit proefschrift zijn gebaseerd op jodium concentraties in de 
urine. Omdat de jodiumuitscheiding een grote fluctuatie van dag to dag vertoont wordt 
deze vaak gerelateerd aan de concentratie van creatinine in het zelfde monster. De 
uitscheiding van creatinine in de urine wordt verondersteld constant te zijn en 
onafhankelijk van de jodium uitscheiding. Naar aanleiding van de resultaten van de 
studie, die beschreven is in hoofdstuk 2, werd besloten om de jodium/creatinine-
verhouding niet te gebruiken aangezien de onafhankelijkheid van deze maatstaf niet 
104 
was gegarandeerd. 
In hoofdstuk 3 wordt een model geïntroduceerd, dat het niet-linieare 
uitscheidingspatroon van jodium in de urine beschrijft tussen de 4 en 44 weken na 
toediening van de gejodeerde olie. Dit model is een hyperbool die de omgekeerd 
evenredige relatie beschrijft tussen de opname-capaciteit voor jodium en de snelheid, 
waarmee de jodium wordt uitgescheiden. Met behulp van dit model kan een 
effectiviteitsduur berekend worden voor een bepaald type olie of voor proefpersonen met 
een bepaald kenmerk. Hiervoor dient een waarde vastgesteld te worden voor een jodium 
concentratie in de urine die geassocieerd wordt met jodiumgebrek (0.40 /xmol/L; door 
UNICEF, de Wereldgezondheidsorganisatie en ICCIDD (International Council for Control 
of Iodine Deficiency Disorders) vastgesteld voor middelmatig jodiumgebrek). Deze 
methode werd gebruikt om de effectiviteit te bepalen van olie A, olie B en voor olie A 
wanneer de dosis in 2 keer de helft werd toegediend. Uit het onderzoek bleek dat de 
opname-capaciteit voor olie B hoger is dan voor olie A en dat de uitscheidingssnelheid 
lager is voor olie B. De effectiviteitsduur voor olie B is 55.2 weken. Voor een enkele en 
een gedeelde dosis olie A is dat slechts 13.7 en 9.9 weken. De conclusie is dan ook dat 
alleen olie B in aanmerking dient te komen voor orale toediening. De effectiviteitsduur 
van olie A wordt niet verlengd door de dosis over twee opeenvolgende dagen te verdelen. 
In hoofdstuk 4 wordt gekeken naar het effect van behandelingen tegen 
darmparasieten op de effectiviteit van olie type A. Het verschil in effectiviteitsduur tussen 
de behandelde en onbehandelde proefpersonen, ongeacht de darmparasieten soort, was 
ongeveer 2 maanden. In deze studie was het effect van het niet behandelen tegen 
Enamoeba histolytica opmerkelijk; de effectiviteitsduur van olie A bedroeg slechts 2 
weken. Voor kinderen die wel behandeld waren tegen deze darm parasiet was de 
effectiviteitsduur 21 weken. Dit betekent dat deze amoebe waarschijnlijk de absorptie van 
olie A verstoort. Entamoeba histolytica houdt zich op in de dikkedarm. Gezien het feit dat 
de absorptie van vet plaats vindt in de dunne darm, zijn de resultaten voor wat deze 
amoebe betreft moeilijk te verklaren. Een mogelijke verklaring is dat de absorptie van 
ethylesters van vetzuren, zoals in olie A, niet vanuit de dunnedarm maar vanuit de 
dikkedarm plaatsvindt. Als dit inderdaad het geval zou zijn, dan kan dit probleem 
mogelijk opgelost worden door een gejodeerde olie te kiezen die uit triacylglycerolen 
bestaat, zoals olie B, aangezien de absorptie van triacylglycerolen plaatsvindt in de 
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dunnedarm. Het effect van Ascaris lumbricoides en mijnworm, beide parasieten van de 
dunnedarm, op de effectiviteit van olie B zal dan opnieuw onderzocht moeten worden. 
In hoofdstuk 5 wordt de rol die de voedingstoestand van de proefpersonen speelt in 
de effectiviteit van gejodeerde olie ter bestrijding van jodium deficiëntie bestudeerd. 
Kinderen met relatief veel subcutaan vet hebben een verhoogde retentiecapacitieit en 
daardoor een langere effectiviteitsduur vergeleken met kinderen met subcutaan vet 
hebben. Gejodeerde vetzuren worden waarschijnlijk opgeslagen in het vetweefsel. Een 
afname in bovenarmomvang, een indicatie voor de eiwit-energie voedingstoestand, leidde 
tot een verlengde duur van effectiviteit. Dit suggereert dat jodium ook in het spierweefsel 
wordt opgeslagen. Naar aanleiding van deze resultaten is het advies dat gejodeerde olie 
het beste op een moment toegediend kan worden wanneer de voedingstoestand van de 
mensen optimaal is. Voor Malawi is dit aan het einde van het oogstseizoen, in oktober. 
De kinderen met krop bleken een veel hogere opname capaciteit voor jodium te hebben 
en, ondanks een eveneens hogere uitscheidingsnelheid, was de effectiviteitsduur ongeveer 
4 maanden langer in vergelijking met kinderen zonder krop. De verhoogde 
opnamecapaciteit kan verklaard worden door een verhoogde activiteit van de schildklier 
om jodium op te nemen. Een mechanisme in de schildklier, om vervolgens van het 
jodiumoverschot af te komen, is waarschijnlijk verantwoordelijk de verhoogde 
uitscheidingssnelheid. 
In de hierboven beschreven onderzoeken werden de patronen in 
jodiumuitscheiding voor kinderen met bepaalde karakteristieken vergeleken op 
groepsniveau. In hoofdstuk 6 wordt de effectiviteitsduur per individu berekend. Een 
frequentie verdeling van de individueel berekende duur van effectiviteit werd uitgezet 
tegen de tijd. Dit geeft informatie over de prevalentie van jodiumdeficiëntie op 
willekeurige tijdstippen na de behandeling. Op deze manier kon de effectiviteit van olie A 
worden vergeleken met die van olie B. Tevens kon hierdoor worden vastgesteld hoeveel 
proefpersonen geen baat hadden bij de behandeling. De prevalentie van jodium deficiëntie 
steeg aanzienlijk sneller voor de proefpersonen die olie A hadden toegediend gekregen. 
Het aantal proefpersonen dat geen baat had bij de behandeling was lager voor olie B (3.1 
%) dan voor olie A (11.1 %). Voor meisjes en voor diegenen die rauwe cassava 
consumeren blijkt dat de prevalentie voor jodium deficiëntie sneller toeneemt dan voor 
jongens en voor diegenen die geen rauwe cassave eten. De conclusie luidt dat meisjes 
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meer jodium nodig hebben of frequenter gedoseerd moeten worden dan jongens. 
Hetzelfde geldt voor personen die rauwe cassave consumeren. 
Tot slot worden in hoofdstuk 7 aanbevelingen gedaan om het gebruik van orale 
toediening van gejodeerde olie zo effectief mogelijk te laten plaatsvinden, en om de 
evaluatie van programma's, waarin gejodeerde olie oraal wordt toegediend, te 
vergemakkelijken. Als noodoplossing is gejodeerde olie uitermate geschikt voor oraal 
gebruik mits de olie uit triacylglycerolesters van gejodeerde vetzuren bestaat. Deze olie 
moet één maal per jaar toegediend worden, bijvoorkeur aan het einde van het 
oogstseizoen. Wanneer er onvoldoende gejodeerde olie beschikbaar moeten meisjes en 
vrouwen de voorkeur genieten boven jongens en mannen. 
Voor evaluatie en onderzoeksdoeleinden is het beter om naar de mediaan van de 
jodiumconcentratie in urine te kijken in plaats van het gemiddelde aangezien de jodium-
concentraties niet normaal verdeeld zijn. De jodium concentratie in de urine dient niet te 
worden gerelateerd aan de creatinine concentratie. Het probleem van dag tot dag variatie 
in de jodium concentratie van urine monsters kan ondergevangen worden door het 
bereken van een gemiddelde van monsters die op opeenvolgende dagen genomen zijn. De 
uitscheiding van jodium in de urine na orale toediening van gejodeerde olie kan 
gejodeerde olie kan beschreven worden door een wiskundige model. Met een minimum 
van drie meetpunten in de tijd kan van een relatief kleine groepen mensen de 
effectiviteitsduur worden berekend in een bepaalde populatie. De frequentie verdeling van 
de individueel berekende effectiviteitduur biedt de mogelijkheid om informatie te krijgen 
over de prevalentie van jodiumdeficiëntie op ieder gewenst tijdstip na toediening van de 
gejodeerde olie. 
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